United States

Environmental

Protection Agency

Guidance for Sample Collection for *In Vitro* Bioaccessibility Assay for Arsenic and Lead in Soil and Applications of Relative Bioavailability Data in Human Health Risk Assessment

January 4, 2021

TABLE OF CONTENTS

ACRONYMS AND ABBREVIATIONS

ABA	Absolute bioavailability
AF_{S+D}	Parameter representing the absorption fraction for soil and dust in the ALM
AFP_{soil}	Parameter representing the absorption fraction percent for soil lead in the IEUBK model
AFP_{water}	Parameter representing the absorption fraction percent of lead in drinking water in the IEUBK model
AL	Action level
ALM	Adult Lead Methodology
APHIS	Animal and Plant Health Inspection Service
ASTM	American Society for Testing and Materials
BAC	Bioavailability Committee (of the OSRTI TRW)
CERCLA	Comprehensive Emergency Response and Liability Act
CI	Confidence interval
CL	Confidence limit
CV	Coefficient of variation
DI	Daily intake of a soil contaminant
DQO	Data quality objective
EPC	Exposure point concentration
H_0	Null hypothesis
H_1	Alternative hypothesis
HDPE	High density polyethylene
HHRA	Human health risk assessment
IC	Incremental composite
ICS	Incremental composite sampling
IEUBK model	Integrated Exposure Uptake Biokinetic Model for Lead in Children
INAA	Instrumental neutron activation analysis
ISM	Incremental sampling method
ITRC	Interstate Technology and Regulatory Council
IVBA	*In vitro* bioaccessibility
LCL95	95% lower confidence limit on the mean
M_{SD}	fraction of door dust contributed by soil
OSHA	Occupational Safety and Health Administration
OSRTI	Office of Superfund Remediation and Technology Innovation
PCT95	95th percentile
QAPP	Quality Assurance Project Plan
RBA	Relative bioavailability
RfD	Reference Dose
SD	Standard deviation
SE	Standard error
SOP	Standard operating procedure
TRW	Technical Review Workgroup
TWA	Time-weighted average
95UCL	95% upper confidence limit
U.S. EPA	United States Environmental Protection Agency
USDA	U.S. Department of Agriculture
XRF	X-ray fluorescence

EXECUTIVE SUMMARY

The U.S. Environmental Protection Agency (U.S. EPA) *Guidance for Sample Collection for In Vitro Bioaccessibility Assay for Lead (Pb) in Soil* (U.S. EPA, 2015) focused on sample collection for assessment of *in vitro* bioaccessibility (IVBA) and relative bioavailability (RBA) of lead. This 2020 guidance supplements U.S. EPA (2015) to include both arsenic and lead, and to address in greater detail the evaluation and analysis of IVBA and RBA data, and applications of RBA to human health risk assessment (HHRA). The purpose of the guidance is to provide information that will assist risk assessors and risk managers in collecting and effectively utilizing data on IVBA and RBA of arsenic and lead for use in HHRA. The guidance provides recommendations on the following major topics:

(1) rationale for collecting RBA data to support HHRA;

(2) application of IVBA and RBA data in HHRA;

(3) evaluation and analysis of IVBA and RBA data for use in HHRA;

(4) systematic planning for collection of RBA data; and

(5) collection and processing of soil samples for measurement of arsenic and lead IVBA at sites.

Topics 1 through 4 are addressed sequentially in Sections 3, 4, 5, and 6 of the guidance. Collection and processing of soils are addressed in Sections 7–10. Appendix A describes an approach to estimating minimum sample numbers needed for RBA assessments and provides examples of sample number calculations for various sampling designs, including discrete sampling and incremental sampling methods (ISM). A list of frequently asked questions about bioavailability sampling and assessment is provided in Attachment A. Attachments B–H provide practical examples of applications of RBA data to site-specific HHRAs.

Reference:

U.S. EPA (U.S. Environmental Protection Agency). (2015) Guidance for Sample Collection for *In Vitro* Bioaccessibility Assay for Lead (Pb) in Soil. U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response: Washington, DC. OSWER 9200.3-100. March. Available online at: http://semspub.epa.gov/src/document/HQ/100000002.

1.0 PURPOSE AND ORGANIZATION OF THIS GUIDANCE

The purpose of this guidance is to provide information that will assist risk assessors and risk managers in collecting and effectively utilizing data on *in vitro* bioaccessibility (IVBA) and relative bioavailability (RBA) of arsenic and lead for use in human health risk assessment (HHRA). The guidance provides recommendations on the following major topics:

(1) rationale for collecting RBA data to support HHRA;

(2) application of IVBA and RBA data in HHRA;

(3) evaluation and analysis of IVBA and RBA data for use in HHRA;

(4) systematic planning for collection of RBA data; and

(5) collection and processing of samples for measurement of arsenic and lead IVBA at sites.

Topics 1 through 4 are addressed sequentially in Sections 3, 4, 5, and 6 of the guidance. Collection and processing of soils are addressed in Sections 7–10. Appendix A describes an approach to estimating minimum sample numbers needed for RBA assessments and provides examples of sample number calculations for various sampling designs, including discrete sampling and incremental sampling methods (ISM). A list of frequently asked questions about bioavailability sampling and assessment is provided in Attachment A. Attachments B–H provide practical examples of applications of RBA data to site risk assessments. Additional information and assistance with RBA assessments can be found at the U.S. Environmental Protection Agency (U.S. EPA) Technical Review Workgroup (TRW) Bioavailability Committee (BAC) website (https://www.epa.gov/superfund/soil-bioavailability-superfund-sites-technical-assistance) or can be obtained by contacting the BAC through its email or hotline (bahelp@epa.gov; 1-866-282-8622).

2.0 BIOAVAILABILITY TERMINOLOGY USED IN THIS GUIDANCE

Absolute bioavailability (ABA): Fraction of an ingested dose of the contaminant (arsenic or lead) that is absorbed from the gastrointestinal tract and enters the blood and tissues.

Relative bioavailability (RBA): Ratio of the ABA of the contaminant in the medium of interest to that of the same contaminant in the medium used to dose the test organism in the oral toxicity studies.

In vitro bioaccessibility (IVBA): Fraction of total amount of arsenic or lead in a soil sample that is soluble in a gastric-like (i.e., low pH) extraction medium.

RBA-adjusted action level (AL): Soil AL for the contaminant after adjustment relative to the RBA assumed in the AL.

RBA-adjusted concentration: Concentration of contaminant in soil after adjustment for RBA; distinguished from the unadjusted or *total concentration* of the contaminant in soil.

RBA-adjusted daily intake (DI): Estimated DI of the contaminant after adjustment for RBA.

3.0 RATIONALE FOR ASSESSING SOIL ARSENIC OR LEAD RBA

Soil RBA is dependent on physical and chemical properties of the arsenic or lead species, and co-occurring elements at any particular site or location within a given site. Accordingly, site-specific estimates of arsenic or lead RBA in soil from representative exposure areas of the site will increase confidence in estimates of risk related to site-specific exposures (U.S. EPA, 1989, 2007a, 2007b, 2012b, 2017b).

Health risk from ingestion of arsenic-contaminated soils is estimated by comparing the estimated daily soil arsenic ingestion intake to a chronic oral Reference Dose (RfD) or to an intake corresponding to a specific cancer risk defined by a cancer oral slope factor. The toxicity values (slope factors, RfD) were derived from human studies in populations chronically exposed to arsenic in drinking water. However, oral bioavailability of arsenic in soil can be substantially lower than soluble arsenic in drinking water (U.S. EPA, 2012b). RBA assessments provide information needed to adjust risk estimates to account for the differences in bioavailability of arsenic in water and soil. If these adjustments are not made, human health risk from ingestion of arsenic-contaminated soils will be overestimated.

Human health risk for lead in soil, where the probability of exceeding a blood lead concentration is used as a proxy for risk, is estimated by applying either the Integrated Exposure Uptake Biokinetic Model for Lead in Children (IEUBK model) for residential exposure scenarios or the Adult Lead Methodology (ALM) for non-residential exposure scenarios to predict blood lead concentrations (U.S. EPA, 2003c, 2007a). Embedded in these models is a default assumption that the RBA of lead in soil is 0.6 (RBA of lead in soil is 60% of the RBA of lead in drinking water). This assumption results in absorption fraction values of 0.3 for soil (at lead intakes below saturation) in the IEUBK model and 0.12 in the ALM. However, soil lead RBA at specific sites can vary considerably from the default RBA value used in the models. RBA assessments provide information needed to adjust bioavailability parameters in models to account for the site-specific difference between bioavailability of soil lead at the site and the value assumed in the models. If these differences are ignored, human health risk from soil ingestion may be under- or overestimated, depending on the actual RBA at the site.

Estimates of RBA can be used in various ways to adjust human health risk estimates for ingestion of arsenic or lead in soil. This guidance specifically addresses four types of RBA adjustments applied to the following risk estimation or risk-based decision parameters (see Section 7):

- soil and dust lead bioavailability parameters in the IEUBK model and ALM

- exposure point concentrations (EPCs);

- DIs of arsenic; and

- soil action levels (ALs) (or other risk-based levels, such as screening levels).

4.0 LABORATORY METHODS FOR MEASURING RBA

Various animal models (e.g., monkey, mouse, rabbit, rat, swine) have been used to study oral bioavailability of arsenic or lead in soil. Information on appropriate bioassays and pertinent primary literature can be found in U.S. EPA (2019a, 2019b). Bioassays using these models estimate RBA from measurements of tissue levels or urinary levels in relation to the oral dosage of arsenic or lead.

U.S. EPA has validated an IVBA assay for predicting soil arsenic and lead RBA for use in HHRA and recommends using the IVBA assay for characterizing site-specific soil arsenic or lead RBA (U.S. EPA Method 1340; U.S. EPA, 2017b, 2017c). The assay involves a simulated gastric-phase extraction of arsenic or lead from soil in a relatively simple extraction medium. Information on these assays and pertinent primary literature can be found in U.S. EPA (2019a, 2019b). In brief, after drying and sieving, 1 g of soil sample is rotated with 100 mL of buffered extraction fluid at 37 ± 2 °C for 1 hour. The supernatant is separated from the soil sample by filtration and analyzed for arsenic and lead by an appropriate analytical method (e.g., U.S. EPA Method 6010 or 6020). Recommendations for sample collection and preparation are provided in Sections 7 and 8 of this guidance. Information on arsenic or lead concentration is used to select samples for the assay to ensure that concentrations do not exceed method limits (see Section 7.1). Results from the IVBA assay (percent or fraction of arsenic or lead that is bioaccessible) are used to predict RBA from a regression model relating IVBA to RBA (described below).

The IVBA assay is a substantially less expensive alternative to an animal bioassay for assessing RBA. The relatively low cost of the IVBA assay compared to an animal bioassay, availability of standard operating procedures (SOPs), and availability of public and commercial laboratories where it can be performed, allows soil samples to be processed more rapidly for the same cost as a single animal bioassay while reducing animal testing. Using the IVBA assay to evaluate multiple soil samples at a site can provide a more thorough assessment of site RBA. However, it is prudent to conduct confirmatory animal RBA bioassays before using an IVBA assay to assess RBA of novel soil types that were not represented in the data used to validate the IVBA assay. These may include soils with chemical and physical characteristics outside the domain of soils used to develop and validate the IVBA assay. It may also include soils that have received treatments with amending agents that alter mobility or solubility of arsenic or lead. For example, IVBA methods have not been validated for predicting RBA of lead in soils amended with high levels of phosphate to reduce lead bioavailability. Additional information on limitations of the IVBA assays can be found in the technical literature available on the U.S. EPA TRW BAC website or can be obtained by contacting the BAC through its email or hotline (bahelp@epa.gov; 1-866-282-8622).

RBA is predicted from IVBA using a regression model (U.S. EPA, 2017b). The regression model for converting arsenic IVBA to arsenic RBA is as follows:

$$arsenic\ RBA\ percent = 0.79 \times IVBA\ percent + 3$$

The regression model for converting lead IVBA to lead RBA is as follows:

$$lead\ RBA\ percent = 0.878 \times IVBA\ percent - 2.8$$

Note that, in both of the above equations, RBA and IVBA and the regression intercept are expressed as percents. If the IVBA data from the laboratory are reported as fractions, rather than as percents, then the corresponding equation for arsenic RBA, expressed as a fraction, is as follows:

$$arsenic\ RBA\ fraction = 0.79 \times arsenic\ IVBA\ fraction + 0.03$$

and the corresponding equation for the RBA fraction for lead is as follows:

$$lead\ RBA\ fraction = 0.878 \times lead\ IVBA\ fraction - 0.028$$

5.0 APPLICATION OF RBA TO HHRA

5.1 RBA Adjustments of Bioavailability Parameters in Lead Risk Models

The IEUBK model includes a parameter that is used in the calculation of the absorption fraction for soil lead (AFP_{soil}, U.S. EPA, 1994). Users adjust this parameter for RBA when site-specific RBA is to be included in the IEUBK model prediction of the child blood lead distribution. The adjustment is as follows:

$$adjusted\ AFP_{soil} = RBA\ fraction \times 50$$

where RBA is expressed as a fraction, and 50 is the IEUBK model assumption for the absorption fraction percent of lead in drinking water (AFP_{water}). The IEUBK model includes a default value of 0.3 for AFP_{soil}, which is equivalent to a default RBA fraction of 0.6 multiplied by the AFP_{water} (50%). A detailed explanation of how to make an RBA adjustment of the IEUBK model is provided in Attachment B (*Calculation of IEUBK Model and Adult Lead Methodology (ALM) Absorption Fraction Parameters from IVBA Results of EPA Method 1340*). An example of an assessment of RBA for the purpose of adjusting the soil absorption parameter in the IEUBK model is provided in Attachment G (*Relative Bioavailability Adjustment of Absorption Fraction Parameters in the Integrated Exposure Biokinetic Model for Lead in Children and Adult Lead Methodology: Cherokee County Railroad Site Case Study*).

The ALM includes a parameter that represents the absorption fraction of ingested lead in soil and dust lead. Users adjust this parameter for RBA when site-specific RBA is to be included in the ALM prediction of the fetal blood lead distribution. The adjustment is as follows:

$$adjusted\ AF_{S+D} + dust = RBA\ fraction \times 0.2$$

where AF_{S+D} is the ALM parameter for the gastrointestinal absorption fraction of lead in soil and dust, RBA is expressed as a fraction, and 0.2 is the ALM default assumption for the absorption fraction of soluble lead (U.S. EPA, 2003c). A detailed explanation of the adjustment of how to make an RBA adjustment of the ALM is provided in Attachment B (*Calculation of IEUBK Model and Adult Lead Methodology (ALM) Absorption Fraction Parameters from IVBA Results of EPA Method 1340*). An example of an RBA assessment of RBA for the purpose of adjusting the soil absorption parameter in the IEUBK model is provided in Attachment G (*Relative Bioavailability Adjustment of Absorption Fraction Parameters in the Integrated Exposure Biokinetic Model for Lead in Children and Adult Lead Methodology: Cherokee County Railroad Site Case Study*).

5.2 RBA Adjustment of a Soil Exposure Point Concentration (EPC)

The EPC should represent the average exposure experienced by the receptor within the exposure unit or decision unit (U.S. EPA, 2002b). For contaminants other than lead, removal and remedial decisions are often made at sites based, in part, on a calculation of the risk from the EPC using a toxicity value (e.g., oral RfD, oral cancer slope factor), which represents an upper limit of the DI of the contaminant in soil that poses negligible risk. The EPC can be adjusted to account for differences between the bioavailability of the contaminant in soil and the bioavailability assumed in the derivation of the toxicity value or screening level. This adjustment facilitates comparisons of EPCs to screening levels that are based on specific RBA assumptions. In lead risk assessments, RBA-adjusted EPCs can be used in batch file processing of input data for the IEUBK model. The adjustment is as follows:

$$adjusted\ EPC = EPC \times RBA\ fraction$$

4

where RBA is expressed as a fraction. An example of an assessment of RBA for the purpose of adjusting an EPC for arsenic and lead is provided in Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study*).

5.3   Adjustment of a Soil Contaminant Daily Oral Intake

For contaminants other than lead, removal and remedial decisions are made at sites based, in part, on comparison of the oral DI of a contaminant to a toxicity value such as a chronic oral RfD, which represents an upper limit of the contaminant intake soil that poses negligible risk. The DI for arsenic can be adjusted to account for differences between the bioavailability of the contaminant in soil and the bioavailability assumed in the derivation of the RfD. The adjustment is as follows:

$$adjusted\ DI = DI \times RBA\ fraction$$

where RBA is expressed as a fraction. An example of an assessment of RBA for the purpose of adjusting an oral DI for soil arsenic is provided in Attachment D (*Bioavailability Adjustment of Daily Oral Intake of Arsenic in a Baseline Human Health Risk Assessment: A Case Study*). An example of how to adjust a time-weighted soil lead concentration is provided in Attachment H (*Relative Bioavailability Adjustment of Soil Lead Exposure Point Concentrations for a Time-Weighted Exposure to Soil*).

5.4   RBA Adjustment of a Soil Risk-based Screening Level or Action Level (AL)

At sites where removal and remedial decisions are made based, in part, on comparison of the EPC to an AL or risk-based concentration or screening level, the AL can be adjusted to account for differences between the bioavailability of the contaminant in soil and the bioavailability assumed in the derivation of the AL. The adjustment should be made to the AL or to the EPC (see Section 5.3), but not to both. The exact adjustment to be made will depend on what assumptions about RBA are incorporated into the AL. For example, if a soil AL for arsenic has been derived assuming an RBA for arsenic of 1.0, then a site-specific RBA adjustment of the AL must be a value relative to 1. For example:

$$adjusted\ AL = AL \times 1.0/RBA\ fraction$$

where RBA expressed as a fraction. An example of adjustment of a soil AL for arsenic is presented in Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*). Lead ALs derived from the IEUBK model that assume that the default model RBA value of 0.6 (absorption fraction for lead in soil = 0.3, absorption fraction for lead in drinking water = 0.5) would be adjusted as follows:

$$adjusted\ AL = AL \times 0.6/RBA\ fraction$$

An example for the adjustment of a risk-based concentration for lead is provided in Attachment F (*Relative Bioavailability Adjustment of a Risk-Based Concentration for Lead: A Case Study – Adjusting RBA in the IEUBK Model and ALM*).

6.0   SYSTEMATIC PLANNING FOR COLLECTION OF RBA DATA

6.1   Data Quality Objectives for RBA Assessment

A Data Quality Objective (DQO) process is used to establish performance or acceptance criteria, which serve as the basis for designing a plan for collecting data of sufficient quality and quantity to support site assessment and remedial decision making. As with planning any environmental sampling,

DQOs should be developed for RBA data collection. See the *Guidance on Systematic Planning Using the Data Quality Objectives Process* (U.S. EPA, 2006) for further discussion. The development of DQOs is a 7-step process:

    (1) state the problem;

    (2) identify the goal of the study;

    (3) identify information inputs;

    (4) define the boundaries (in space and time) of the study;

    (5) develop the analytical approach;

    (6) specify the performance criteria; and

    (7) develop a detailed plan for obtaining the data.

The final step of the DQO process is to develop a sampling and analysis plan. This plan should consider potential soil exposure pathways for the site and any existing site data. If existing sampling data are available for a site, the information could assist in understanding the variability of data at the site and in planning a representative sampling design. Samples collected to assess RBA and total metal concentrations should be representative of the bioavailability throughout the area of exposure (i.e., the exposure unit). The *Guidance on Choosing a Sampling Design for Environmental Data Collection for Use in Developing a Quality Assurance Project Plan* is a useful resource for selecting a design to meet the project DQOs and provide representative data (U.S. EPA, 2002a). An example of application of DQOs to RBA assessment is presented in Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study*). Consultation with a qualified statistician who has experience with sampling design is recommended.

6.2   Retrospective RBA Assessments of Archived Soil Samples

Retrospective RBA assessments are sometimes undertaken at sites based on RBA measurements made on archived soils collected for some other purpose (e.g., discovery, preliminary site characterizations, assessments to support removal decisions). In these instances, the original sampling design may not have considered DQOs for characterizing RBA. Therefore, development of a DQO for RBA assessment based on the archived soils is advised so that an appropriate approach to selecting soils for RBA measurement may be developed. For example, if the DQO is to estimate a site-wide RBA value, then consideration should be given to whether or not the archived soils actually provide a representative sample of RBA at the site. If not, sources of sampling bias should be identified and incorporated into the approach to selecting soils for RBA measurements. If these biases cannot be controlled with the method used to select samples, then they should be considered in the interpretation of the results and in any decisions that are made based on the results. In the absence of a DQO and appropriate sampling design, RBA assessments would be based on a "convenience sample" (e.g., random sample of the archive), rather than on a statistical sample of the site. Use of convenience samples to estimate a site-wide or area-wide RBA introduces larger uncertainty into the RBA estimate. For this reason, the selection of the statistic to represent the site or area RBA may need to recognize greater uncertainty in the mean. For example, rather than using a mean or 95% upper confidence limit of the mean (95UCL) of the mean, an upper percentile or maximum might be considered to represent RBA at the site. An example of a retrospective RBA assessment at a site based on measurement of the RBA using archived samples is provided in

Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*).

6.3 Evaluation of RBA Data Adequacy

Evaluation of adequacy of RBA data begins with a thorough evaluation of the data against the quality control limits for the methods used to collect the data. Quality control criteria of arsenic and lead IVBA assays can be found in the SOPs for the assay (U.S. EPA, 2017b). Quality evaluation of RBA data also includes evaluation of the implementation of sample collection methods to determine whether or not the sample design was followed and, if not, the causes, effects, and implications of deviations from the plan. Provided that quality control requirements for sampling and analysis have been achieved, adequacy of the RBA data should be evaluated against the DQO for RBA at the site. The DQO should specify performance and acceptance criteria of the data. More information on DQOs and performance criteria can be found in the *Guidance on Systematic Planning Using the Data Quality Objectives Process* (U.S. EPA, 2006). For DQOs that test hypotheses such as, "is the EPC greater than an AL," the collected data should result in acceptable false compliance decision error (Type 1) and false exceedance decision error (Type 2) probabilities. A false compliance decision error occurs if it is concluded that the EPC is less than the AL, when it is actually greater than the AL. This outcome is also referred to as a false rejection error (U.S. EPA, 2006). A false compliance decision error could result in underestimating risk at the site and/or not taking an action when action is needed to reduce risk. A false exceedance decision error occurs if it is concluded that the EPC exceeds the AL, when it is actually less than the AL. This outcome is also referred to as a false acceptance error (U.S. EPA, 2006). A false exceedance decision error could result in overestimating risk at the site and/or taking action at the site to reduce risk when no action is needed. An example of how to estimate decision error probabilities that rely on estimates of RBA-adjusted EPCs is provided in Appendix A (*Guidance for Sample Collection for Estimating an RBA-adjusted Exposure Point Concentration for Soil*). The example is presented from the perspective of systematic planning for data collection; however, the data collected can be analyzed using the same methods to evaluate whether data collected were within acceptable limits of decision error.

6.4 Selection of Appropriate Statistic to Represent RBA at the Site

Selection of a statistic to represent the RBA for a decision unit will depend on the DQO established for the decision. If the RBA is to be used to adjust the EPC for the decision unit (i.e., adjusted EPC = EPC × RBA), the statistic selected to represent the RBA should be consistent with the definition of the EPC [see Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study*)]. Often, in HHRA, the decision unit represents an exposure unit, within which the receptor has an equal probability of being exposed to soil contaminants anywhere within the decision unit. In this context, the EPC should be the average concentration in the decision unit, estimated as the arithmetic mean or the 95UCL of the mean, from a representative set of soil samples collected from the decision unit (U.S. EPA, 1989, 2002b, 2019c). If the EPC is intended to represent the average exposure concentration at the decision unit, then, consistent with the EPC representing the average exposure, the RBA-adjusted exposure should also represent the average and the statistic to be used to represent the RBA should be the mean or 95UCL of the mean.

The RBA may also be used to adjust the AL applied to evaluating the decisions such as whether or not to remediate at the decision unit [e.g., adjusted AL = AL/RBA; Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*)]. This adjustment, conceptually, also represents an adjustment of the EPC, in that an upward adjustment of the AL implies that the EPC can be higher without exceeding the AL. Therefore, the adjustment of the AL should also be

consistent with the definition of the EPC. If the EPC is intended to represent the average exposure concentration at the decision unit, then the mean or 95UCL should be selected to represent the RBA.

In some circumstances, it may be prudent to consider statistics other than the mean (or 95UCL) to represent the RBA [see Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*)]. For example, heterogeneity in RBA within the decision unit, if detected from sampling or inferred from other information about sources of contamination, may prompt consideration of a percentile to represent the RBA. The selection of the percentile will depend on the observed distribution of RBA within the decision unit. The RBA distribution can be estimated from a properly designed discrete sampling plan. In selecting a percentile rather than a mean to represent the RBA, the resulting adjusted EPC or AL will no longer represent the average adjusted exposure. This bias may be warranted on the basis of ensuring that risk is not underestimated at a decision unit in which there is high variability in RBA. Selection of an upper percentile to represent the RBA at the decision unit will decrease false compliance decision error and increase false exceedance decision error [see Appendix A (*Guidance for Sample Collection for Estimating an RBA-adjusted Exposure Point Concentration for Soil*), for further explanation of decision errors].

6.5   Estimation of a Site-wide RBA from RBA Data for Multiple Decision Units

A site-wide RBA may be estimated to simplify risk assessment calculations at sites where RBA is found be (or is assumed to be) homogenous across decision units. The method used to estimate a site-wide RBA will depend on the DQO and the conceptual site model (i.e., how well decision units represent the site), as well as the distribution of observed RBAs in the decision unit.

Use of a site-wide RBA to adjust decision EPCs or decision unit ALs: Often, in HHRA, the decision unit represents an exposure unit, within which the receptor has an equal probability of being exposed to soil contaminants anywhere within the decision unit. In this context, the EPC representing exposure within the decision unit should be the average concentration in the decision unit, estimated as the arithmetic mean or the 95UCL of the mean. The assumption of equal probability of exposure may not apply across decision units. If it did, the entire site could be considered a single decision unit. If exposure cannot be assumed to be random across the site, then use of a site-wide RBA to adjust decision unit EPCs or ALs is not advised, and these adjustments should be made at the decision unit level. If a site-wide RBA is to be used to assess risk at the decision unit level, and exposure is not random across the site, then some form of spatial or activity weighting of the decision units should be considered in the calculation of a site-wide RBA. However, it must be kept in mind that a weighted or unweighted estimate of a site-wide RBA (e.g., weighted mean) may over- or underestimate RBA at any given decision unit and, as a result, there will be lower confidence in the resulting adjusted EPC or adjusted AL for the decision unit if adjusted by a site-wide RBA. For this reason, consideration should be given in decision unit-level assessments for measuring RBA at each decision unit being assessed. If only a subset of decision units is assessed for RBA, then the DQO should address the following: (1) plan for selecting decision units for RBA measurement that ensures that resulting data can be used to predict RBAs at these decision units that are not selected for RBA measurement and (2) statistic to be used to represent the RBA at decision units not selected for measurement of RBA [see Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study]*).

Use of a site-wide RBA to characterize RBA variability at the site: Assessment of site-wide variability in RBA can support decisions to assess RBA at the decision unit level. It may also reveal heterogeneity in RBA across the site that may be related to multiple sources of contamination with materials that have different RBA. If the objective is to understand variability in RBA at the site, then decision unit RBAs can be analyzed in a variety of ways, including probability plots and spatial

distribution plots. The outcome of these analyses will determine how the site-wide RBA is to be estimated (e.g., unweighted or spatially weighted statistics).

6.6   Use of the Conceptual Site Model to Inform RBA Sampling

Selection of an appropriate sampling design and sample numbers used to assess RBA at a site will depend, in part, on the RBA variability at the site. Often, in developing sampling design to support a DQO, accurate information of RBA variability may not be available (e.g., if site was not previously sampled) and would have to be assumed. These assumptions can be informed by the conceptual site model, which may identify factors that could contribute variability of RBA across the site. Examples of these factor include:

- Would the source(s) of contamination be expected to result in low or high variability in RBA? For example, multiple sources may release different forms of arsenic or lead, which could have different RBAs, depending on the initial source of contamination, timing of release, and environmental conditions that affect leaching and redistribution of the contamination and mixing with background sources.

- Does the soil or sediment geochemistry vary across the site? For example, local and regional variability in soil characteristics could contribute to RBA variability across the site.

- What are the expected soil concentrations? For example, decisions about contaminant concentrations that are more than 100 times the AL may not be appreciably affected by RBA assessments.

6.7   Use of Soil Concentration Data to Select Samples for RBA Measurement

RBA of soil arsenic and lead can be expected to range from 0 to 100%. Over the RBA range of 1 to 100%, adjustments of the EPC or AL to account for RBA will be less than a factor of 100, and decisions about contaminant concentrations (removal, remediation, control) that are more than 100 times the AL may not be appreciably affected by RBA assessments.

Large variations in concentrations across the site may also be indicative of multiple sources of contamination and, possibly, associated variation in RBA. This information may be useful for developing sampling designs in the DQO process. However, selection of soils for RBA assessment based on contaminant concentrations should be done in a manner that avoids biasing the data. The DQO planning process should be used to ensure that the resulting data can satisfy the DQO. For example, if the DQO is to estimate a site-wide RBA, selection of soils based on concentration may bias the site-wide estimate if some areas are sampled much less densely than others. This consideration is particularly important if the RBA results are to be used to predict RBA based on concentrations at locations where RBA was not measured.

An alternative to selection of soils for RBA assessment based on concentration is to select a random sample of soils and then analyze the data for RBA variance attributable to concentration (e.g., analysis of variance, regression modeling). Often, this approach may be preferable, given the relatively low additional expense of IVBA assays, the importance of understanding variability, and the need for samples to be representative (i.e., in addition to the expense of contaminant concentration measurements).

6.8   Use of Information on Mineralogy and Speciation to Select RBA Samples and Methods

Information on mineralogy and speciation can be useful to explain RBA variability at the site. This information may be useful for developing sampling designs in the DQO process. Speciation of soil metals is a technically complex and is often applied to a small subset of samples for the purpose of explaining observed RBA rather than for predicting RBA in advance of measurements. For example, unusual or unexpected RBA values may be followed up with speciation measurements to better understand why the RBA values were observed or to improve predictions of RBA from IVBA.

7.0   SAMPLE COLLECTION

7.1   Data Collection Requirements

The final step of the DQO process is to develop a sampling and analysis plan. This plan should consider potential soil exposure pathways for the site and any existing site data; for example, if the site is a residential area, then evaluation of exposure pathways in children's play areas, gardens, and the drip lines of homes should be given special attention (U.S. EPA, 2003a). If existing sampling data are available for a site, the information could assist in targeting the sampling locations where there is likely exposure to these contaminated areas. Measurements of RBA and total arsenic or lead concentrations should be representative of the area of exposure (i.e., the exposure unit), as well as the depth of exposure for the receptor. The *Guidance on Choosing a Sampling Design for Environmental Data Collection for Use in Developing a Quality Assurance Project Plan* is a useful resource for selecting a design to meet the project DQOs and provide representative data (U.S. EPA, 2002a).

Samples for the IVBA assay should have a total lead concentration of less than 50,000 mg/kg and a total arsenic concentration of less than 13,000 mg/kg (U.S. EPA Method 1340). If the IVBA assay needs to be performed on a sample with a lead concentration greater than 50,000 mg/kg or an arsenic concentration greater than 13,000 mg/kg, the laboratory performing the assays should be informed of the sample concentrations so that the amount of soil used in the IVBA assay can be adjusted to be within the appropriate concentration range. Often, soil samples are collected, submitted for metals analysis, and archived while data are collected and reviewed. Based on the analytical results, a subset of the samples is selected for the IVBA assay. This approach allows the site team to target specific areas within a sampling unit that are suspected of having different bioavailability. It also allows the IVBA samples to target specific total lead or arsenic concentrations that are relevant to decision making. For example, the site team may categorize samples into low, medium, and high total lead concentrations and select a representative subsample from each of those categories for IVBA analysis to evaluate if bioavailability is consistent across the concentration range at the site or to target total lead or arsenic concentrations that are particularly relevant to decision making. At other sites, sample locations could be identified in the sampling plan, and samples for measurement of total arsenic or lead concentration would be collected concurrently and analyzed without prior knowledge of concentrations at the site. Regardless of whether the IVBA sample locations are selected *a priori* or after the total metals concentration analysis is complete, incorporating RBA needs into the DQO process prior to sampling and/or IVBA analysis makes the field effort more efficient, simplifies the data analysis, and clarifies how the data will be used.

The use of portable X-ray fluorescence (XRF) is recommended to screen samples in the field because there is significant savings related to time and financial resources by eliminating the collection of samples that do not meet *a priori* criteria for IVBA analysis (such as concentrations that are below the decision range). There are many advantages of field screening for lead and other metals including a reduction of both laboratory and field work. Soils with little to no metals contamination would not be collected for IVBA analysis, shipped, or processed by laboratory staff. Highly variable soil lead concentrations within a site may be identified in real time by portable XRF in the field, allowing for the

immediate collection of additional samples to better characterize the variability or to form composite samples in the laboratory. Field screening with portable XRF therefore reduces the turnaround time required to generate IVBA results, the need for additional field deployments, and waste generation. Field operators of portable XRF instruments should ensure that they are following appropriate protocols to obtain reliable results (SW-846, Method 6200, U.S. EPA, 2007b). The U.S. EPA *Region 4 Superfund X-Ray Fluorescence Field Operations Guide* provides additional information on the use of portable XRF instruments (U.S. EPA, 2017a). It should be noted that the presence of lead can interfere with XRF measurements of arsenic. Method 6200 states "Arsenic concentrations cannot be efficiently calculated for samples with lead-arsenic ratios of 10:1 or more. This high ratio of lead may result in reporting of a "nondetect" or a "less than" value (e.g., <300 ppm) for arsenic, regardless of the actual concentration present (U.S. EPA, 2007b)."

When collecting samples for IVBA assay, it is important to note site and soil sample characteristics that may suggest differences in the bioavailability of the arsenic or lead or indicate that interferences might be present. For example, the lead IVBA assay (U.S. EPA Method 1340) may not reliably predict RBA of lead in soils that have been amended with phosphate (Scheckel et al., 2013). If phosphate at a site is of concern, the phosphate concentration should be measured. Generally, this interference occurs at phosphate concentrations typical for treating a soil to bind lead and reduce its bioavailability. Naturally occurring levels of soil phosphate are not expected to interfere with Method 1340, and most fertilizers contain little, if any, phosphate. However, soil samples from a garden generally should not be composited with samples from the surrounding land use areas, because a garden exposure pathway would be expected to differ from exposure to the rest of the property and there is some possibility that a garden may have elevated phosphate levels. Likewise, it may not be advisable to composite soil samples from the drip line of a home with the remainder of the property, as lead within the drip line may be from lead paint and warrant special consideration (e.g., unrelated to the Comprehensive Environmental Response, Compensation and Liability Act; CERCLA).

In addition to the total metals and IVBA analyses, speciation analysis and animal bioavailability studies might also be considered. Speciation analysis is meant to determine the exact chemical/ mineralogical form(s), or species, of lead or arsenic in a sample. While speciation analysis is not necessary, it may be informative in explaining variability in IVBA across the site, identifying sources of contamination of the soil, and assessing the potential mobility of arsenic or lead in the soil (see Section 6.8). The IVBA assay is meant to be a faster and less expensive alternative to *in vivo* animal bioavailability studies. However, there may be cases (such as potential interference from soil amendment applications [e.g., phosphate], untested lead phases, etc.) when an animal study may be necessary. It is important to ensure that sufficient material is collected for each soil sample so that additional analyses could be performed. If additional analyses are determined to be necessary, such as lead speciation analysis or *in vivo* animal bioavailability studies, consultation with the TRW BAC is recommended.

Prior to sampling, a determination must be made as to whether the soil is regulated or quarantined by the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS)/ Plant Protection and Quarantine (USDA, 2014). Special care should be taken to segregate regulated or quarantined soil samples from the non-regulated or non-quarantined samples. To determine if the soils collected are regulated or quarantined, contact the State Plant Health Director (https://www.aphis.usda.gov/aphis/ourfocus/planthealth?1dmy&urile=wcm%3apath%3a%2Fap%20his_content_library%2Fsa_our_focus%2Fsa_plant_health%2Fsa_program_overview%2Fct_sphd).

7.2   Number of Samples

The number of samples to collect and analyze for IVBA will depend on the DQO for the study. Factors that should be considered in estimating the number of samples include the following:

- goals of the RBA assessment;

- size and characteristics of the decision units at the site;

- expected variability in RBA within decision units, based on available data or bounding assumptions (U.S. EPA, 2007c); and

- acceptable limits on decision errors (false compliance decision error, false exceedance decision error, and the minimum detectable difference).

Project managers should consult with U.S. EPA *Guidance on Systematic Planning Using the Data Quality Objectives Process* or other appropriate guidance when developing DQOs (U.S. EPA, 2006). In general, sample size estimates for RBA assessments can be based on the same types of power analyses used to evaluate statistical hypotheses in estimating EPCs at decision units (see Appendix A). Chapters 6 and 7 of the DQO Guidance discuss selecting appropriate error rates and the minimum detectable difference, as well as estimating the number of samples needed to achieve those specifications (U.S. EPA, 2006). The anticipated variability of the data determines the number of samples that will be required to achieve the DQOs. Where the data set is expected to be highly variable, more samples will be necessary. Alternatively, the ISM (also referred to as Incremental Composite Sampling, ICS) may be used. This is a type of sample designed to reduce data variability, increase data representativeness, and reduce analytical costs (Brewer et al., 2017; ITRC, 2012). Data generated from ISM tend to be normally distributed, which also simplifies the data analysis. Appendix A discusses sample number calculations for both discrete samples and ISM.

7.3   Sampling Depth

The appropriate sampling depth for a site will depend on the expected exposure pathway for that site. For most scenarios involving exposure to contaminated surface soil, U.S. EPA generally recommends a sampling depth of the top 0–1 inches of soil below organic litter and sod for lead exposure analysis (U.S. EPA, 2020). With this shallow sample depth, obtaining sufficient sample mass for discrete samples may require collecting a larger mass of soil than is typical, especially if the material is particularly coarse. ICS can provide larger masses for shallow samples. If there are other exposure scenarios for a site, other sampling depth intervals that would represent these scenarios should be collected.

7.4   Field Sample Preparation

To ensure that sufficient sample material is available for analysis, the field samplers should consider sieving the material in the field to remove larger debris. Sieve screens No. 4 (4.72 mm) or No. 10 (2.0 mm) would be sufficient for removing larger debris in the field.

7.5   Sample Mass

For metals analysis, SW-846 recommends that a minimum of 200 g of soil be collected and that 2 g of sample be used for the digestions (SW-846, Chapter 3 Inorganic Analytes, Table 3-2, U.S. EPA, 2007a). Method 1340 specifies that 1 g of dried and sieved soil sample be used for IVBA assay of lead for a single replicate (U.S. EPA, 2013a). Additional replicates may be required if the assay does not meet performance specifications for IVBA. The amount of sample required will depend on the particle size distribution of the soil and the moisture content of the soil following coarse sieving in the field. If the

samples will be submitted for animal bioavailability studies or speciation analysis, the laboratories that will be conducting these analyses should be consulted on the amount of sample materials they will require to determine the sample mass needed. For further assistance in determining the sample mass for *in vivo* bioavailability and IVBA assays, please contact the TRW BAC.

8.0 SAMPLING EQUIPMENT AND HANDLING

8.1 Sample Containers

The analytical laboratory/program that will be conducting the metals analysis should be consulted about the appropriate sample container and size required. For the IVBA assay, there are no specific sample container requirements. If no sample container is specified by the metals analysis laboratory, then appropriate containers include glass jars, wide-mouth high density polyethylene (HDPE) jars, plastic zippered bags, or any other container that is clean and free of contaminants can be used. A single one-gallon plastic zippered bag (e.g., plastic freezer bag) should provide sufficient sample material for at least the metals analysis and IVBA assay for most soils. Two-gallon plastic zippered bags may be required for sandy soils and soils with rocks passing through the sieve in the field. If using wide-mouth HDPE jars, a 1000-mL jar should provide sufficient sample, but collect multiple jars per sample if the soil is particularly coarse. There will be considerable cost reduction using a plastic zippered bag compared to a HDPE bottle (both cost of sample containers and shipping).

8.2 Sampling Equipment

For most scenarios involving exposure to contaminated surface soil, U.S. EPA recommends a sampling depth of the top 0–1 inches of soil below organic litter and sod (U.S. EPA, 2020). Collection of surface soil samples may be accomplished with a stainless-steel cylindrical punch, which will capture a constant diameter core for the sampling depth of interest. Sampling using a kick-style cylindrical punch may reduce sample time in the field due to the ease of use. Kick-style punches are not recommended for sandy soils because the soil readily falls out of the probe. Likewise, soils with heavy clay content or rocks are not recommended due to the difficulty in removing clay soils from the equipment and rocky soil will be rejected at the soil surface. For these reasons, using plastic or stainless-steel spades, trowels, or spoons may be preferable, but the sampler should ensure that a sample is collected evenly across the sampling depth. Once the samples are collected, they should be placed in suitable containers for shipment. Any equipment that is not disposable should be thoroughly decontaminated between samples to maintain sample representativeness and prevent cross-contamination, and appropriately stored after sampling. If the exposure pathway being investigated requires deeper sampling depths than 0–1 inches, equipment such as augers, split spoon samplers, and backhoes may be necessary (U.S. EPA, 2000). If sampling at depth, care should be taken during sampling to account for any soil compaction as a result of sampling.

8.3 Field Sieving

Field sieving soils prior to shipment to laboratories decreases the amount of time needed for fine sieving (next section) and reduces the weight of soils and shipping costs through the removal of large soil fractions. Additionally, to help ensure that sufficient sample material is available for analysis, the field samplers should consider sieving the material in the field to remove larger debris (e.g., rocks, grass, sticks). Sieve screens No. 4 (4.76 mm) or No. 10 (2.0 mm) would be sufficient for removing larger debris in the field. The soil that passes through the No. 4 or No. 10 sieve can be collected in new plastic bags (e.g., Ziploc) or if larger amounts of soils are needed, clean plastic buckets. The field-sieved soil must then be sent to the laboratory for fine sieving, drying, and homogenization.

13

8.4 Fine Sieving

Samples should be fine-sieved to a particle size limit appropriate to the exposure scenario (e.g., <150 μm for dermal contact with surface soil (U.S. EPA, 2016). Personal protection equipment (e.g., face mask, lab coat, gloves) should be worn when fine sieving soils in the laboratory. If **possible**, a dust containment system such as a vent hood should be utilized to reduce exposure when sieving highly contaminated soils.

Once in the laboratory, the soil samples should be homogenized and completely dried in an air-drying oven at <40ºC for up to 5 days or until a constant mass. After drying, any clumps in the sample should be gently broken or declumped using a gloved hand in preparation for passing through a No. 10 (2 mm) standard test sieve. **Samples should NOT be ground by ball mill, mortar and pestle, or any other grinding method that could result in reduction in the particle sizes of the collected soils.**

*For sieving bulk soils (not field sieved)***:** Affix a No. 10 (2 mm) stainless steel test sieve on top of a No. 100 (149 µm) standard test sieve, with a receiver pan at the bottom. For soils or field samples with pebbles or conglomerated soil, a No. 3.5 (5.66 mm) sieve can be placed on top of the No. 10 sieve to separate these materials. In cases where clogging of the No. 100 sieve is suspected or observed, sieves of intermediate size (No. 30 or No. 40) may be placed between the No. 10 and No. 100 sieves as needed. **Note**: Brass sieves or sieves with lead solder should NOT be used as they can contaminate samples with trace amounts of heavy metals.

*For fine sieving field soils that were previously sieved***:** Affix a No. 100 (149 µm) standard test sieve, with a receiver pan at the bottom. Fill the attached topmost No. 100 sieve half full with unsieved soil. Disaggregate any large clumps of soil as needed using a gloved hand. Attach cover over top sieve. Place sealed, stacked sieves on the sieve shaker. Power on sieve shaker and sift to <150 µm until visual inspection of the soil indicates that it has been sufficiently sieved (approximately 5–10 minutes for sandy soils and 20–30 minutes for heavy clay soils).

After passing soil though No. 100 sieve: Transfer sieved soils into clean, pre-weighed individual polyethylene bags, or similar toxic element-free storage containers (wide-mouth HDPE jars, aluminum pan, etc.). Label all storage bags/containers with date, soil ID, soil particle size, and personnel initials plus any other information deemed relevant. Repeat sieving until the remaining soil sample is satisfactorily processed. Weigh (± 0.01 g per container) all sieved soils. Record weights of all sieved and collected soils (± 0.01 g per container) in laboratory notebook or electronic database.

To ensure that composite samples are representative of all of the component locations, the entire field sample should be processed (i.e., dried and fine sieved). Following sieving, each sample should be thoroughly mixed using American Society for Testing and Materials (ASTM) standard D6051-96 (ASTM 2006) or Interstate Technology and Regulatory Council (ITRC) Incremental Sampling Methodology (ITRC 2012), and then transferred to a suitable storage container (U.S. EPA, 2013b).

Extractable metals and metalloids analysis using methods appropriate digestion methods (e.g., U.S. EPA Methods 3051a, 3050) or direct metal concentrations (e.g., instrumental neutron activation analysis [INAA], XRF) and other analyses should be conducted on the same dried, sieved, and homogenized sample material that will also be used for the IVBA assay. To split a sample into equivalent aliquots for the different analyses, the processed soil should be passed through a riffle splitter and the aliquots collected in clean, 250-mL high-density polyethylene bottles (U.S. EPA, 2003b). Samples that have been dried and sieved can be submitted for total metals analysis, metals speciation, IVBA assay, and *in vivo* animal bioavailability studies, but should not be used for analysis of other contaminants of concern.

8.5   Labeling, Shipping and Storage Temperature, and Hold Time

Sample ID numbering, labeling, documentation, and chain of custody should follow the requirements of the analytical laboratory/program that will be conducting the metals analysis. The samples may be shipped at ambient temperature unless otherwise specified by the analytical laboratory/ program.

U.S. EPA recommends a holding time of 6 months for metals samples. The Method 1340 SOP recommends that all samples be archived after metal analysis and retained for further analysis, including *in vivo* bioavailability assay, for 6 months (U.S. EPA, 2012a, 2017b). The samples may be stored at ambient temperature unless specified otherwise by the analytical laboratory/program.

9.0   QUALITY ASSURANCE/QUALITY CONTROL

The field samplers should consult with the metals analysis laboratory or the U.S. EPA program to determine in advance the requirements for blanks, duplicates, and matrix spikes for the metals analysis samples. For the IVBA assay, Method 1340 does not require field blanks, field replicates, or matrix spikes to be prepared or collected by field samplers. However, the site team may collect or require these quality assurance samples where appropriate, based on consultation with the analytical laboratory, U.S. EPA program, or a qualified chemist. Material for the matrix spike and replicates for Method 1340 may be taken from the samples at the laboratory's discretion and may not require that samplers collect and designate separate matrix spike and duplicates in the field.

Samplers should take thorough field notes and retain any photographs taken, logbooks, and notes following the sampling event. The field group should make note of any differences in the media between the sample locations and indicate if there are any potential interferences (e.g., phosphate-amended soils) present.

10.0   HEALTH AND SAFETY

When working with potentially hazardous materials, follow U.S. EPA, Occupational Safety and Health Administration (OSHA), and any contractor's corporate health and safety procedures, in addition to the procedures specified in the site-specific Health and Safety Plan.

11.0   REFERENCES

ASTM (American Society for Testing and Materials). (2006) ASTM D6051-96. Standard Guide for Composite Sampling and Field Subsampling for Environmental Waste Management Activities. Book of Standards Volume: 11.04. ASTM International: West Conshohocken, PA. Available online at: http://www.astm.org/Standards/D6051.htm.

Brewer, R., Peard, J., Heskett, M. (2017) A critical review of discrete soil sample data reliability: Part 2 – Implications. Soil Sediment Contam. 26(1):23-24. http://dx.doi.org/10.1080/15320383.2017.1244172.

ITRC (Interstate Technology and Regulatory Council). (2012) Incremental Sampling Methodology. ISM-1. Interstate Technology and Regulatory Council, Incremental Sampling Methodology Team: Washington, DC. February.

Scheckel, K.G., Diamond, G., Maddaloni, M., Partridge, C., Serda, S., Miller, B.W., Klotzbach, J., Burgess, M. (2013) Amending soils with phosphate as means to mitigate soil lead hazard: A critical review of the state of the science. J. Toxicol. Environ. Health B 16(6): 337–380.

USDA (U.S. Department of Agriculture). (2014) State Plant Health Directors. U.S. Department of Agriculture, Animal and Plant Health Inspection Service: Washington, DC. Available online at: http://www.aphis.usda.gov.

U.S. EPA (U.S. Environmental Protection Agency). (1989) Risk Assessment Guidance for Superfund Volume 1 Human Health Evaluation Manual (Part A). U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. EPA/540/1-80/0023. December. Available online at: https://www.epa.gov/risk/risk-assessment-guidance-superfund-rags-part.

U.S. EPA (U.S. Environmental Protection Agency). (1994) Technical Support Document for the Integrated Exposure Uptake Biokinetic Model for Lead in Children (v0.99d). U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. EPA 9285.7-22. December. Available online at: https://www.epa.gov/superfund/lead-superfund-sites-software-and-users-manuals.

U.S. EPA (U.S. Environmental Protection Agency). (2000) Standard Operating Procedure: Soil Sampling. U.S. Environmental Protection Agency: Washington, DC. March.

U.S. EPA (U.S. Environmental Protection Agency). (2002a) Guidance on Choosing a Sampling Design for Environmental Data Collection for Use in Developing a Quality Assurance Project Plan. U.S. Environmental Protection Agency, Office of Environmental Information. Washington, DC. EPA QA/G-5S. EPA/240/R-02/005. December. Available online at: https://www.epa.gov/sites/production/files/2015-06/documents/g5s-final.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2002b) Calculating Upper confidence Limit for Exposure Point Concentrations at Hazardous Waste Sites. U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. OSWER 9285.6-10. July. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100CYCE.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2003a) Superfund Lead-Contaminated Residential Sites Handbook. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OSWER 9285.7-50. August. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100K3UN.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2003b) Guidance for Obtaining Representative Laboratory Analytical Subsamples from Particulate Laboratory Samples. U.S. Environmental Protection Agency, Office of Research and Development: Washington, DC. EPA/600/R-03/027. November. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=2000GTWM.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2003c) Recommendations of the Technical Review Workgroup for Lead for an Approach to Assessing Risks Associated with Adult Exposures to Lead in Soil. U.S. Environmental Protection Agency: Washington, DC. EPA-540-R-03-001, OSWER Directive #9385.7-54. December. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100A16H.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2006) Guidance on Systematic Planning Using the Data Quality Objectives Process. EPA QA/G-4. U.S. Environmental Protection Agency, Office of

Environmental Information: Washington, DC. EPA/240/B-06/001. February. Available online at:
https://www.epa.gov/sites/production/files/2015-06/documents/g4-final.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2007a) SW-846. Chapter Three – Inorganic
Analytes. Revision 4. U.S. Environmental Protection Agency, Office of Resource Conservation and
Recovery: Washington, DC. February. Available online at:
https://www.epa.gov/sites/production/files/2015-10/documents/chap3_1.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2007b) Method 6200 – Field Portable X-ray
Fluorescence Spectrometry for the Determination of Elemental Concentrations in Soil and Sediment.
SW- 846, Update VI. Revision 0. U.S. Environmental Protection Agency, Office of Resource
Conservation and Recovery: Washington, DC. February. Available online at:
https://www.epa.gov/sites/production/files/2015-12/documents/6200.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2007c) Guidance for Evaluating the Oral
Bioavailability of Metals in Soils for Use in Human Health Risk Assessment. U.S. Environmental
Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC.
OSWER 9285.7-80. May. Available online at:
https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=93001C3I.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2012a) Standard Operating Procedure for an *In
Vitro* Bioaccessibility Assay for Lead in Soil. U.S. Environmental Protection Agency, Office of
Superfund Remediation and Technology Innovation: Washington, DC. EPA 9200.2-86. April. Available
online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100GESL.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2012b) Compilation and Review of Data for
Relative Bioavailability of Arsenic in Soil and Recommendations for Default Value for Relative
Bioavailability. U.S. Environmental Protection Agency, Office of Superfund Remediation and
Technology Innovation: Washington, DC. EPA 9200.1-113. December. Available online at:
https://www.epa.gov/superfund/soil-bioavailability-superfund-sites-guidance#arsenic.

U.S. EPA (U.S. Environmental Protection Agency). (2013a) Method 1340 – *In Vitro* Bioaccessibility
Assay for Lead in Soil. SW-846, Update VI. Revision 0. U.S. Environmental Protection Agency, Office
of Resource Conservation and Recovery: Washington, DC. November.

U.S. EPA (U.S. Environmental Protection Agency). (2013b) The Roles of Project Managers and
Laboratories in Maintaining the Representativeness of Incremental and Composite Soil Samples. U.S.
Environmental Protection Agency, Office of Solid Waste and Emergency Response: Washington, DC.
OSWER 9200.1-117FS. June. Available online at:
http://www.clu-in.org/download/char/RolesofPMsandLabsinSubsampling.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2015) Guidance for Sample Collection for *In Vitro*
Bioaccessibility Assay for Lead (Pb) in Soil. U.S. Environmental Protection Agency, Office of Solid
Waste and Emergency Response: Washington, DC. OSWER 9200.3-100. March. Available online at:
http://semspub.epa.gov/src/document/HQ/100000002.

U.S. EPA (U.S. Environmental Protection Agency). (2016) Recommendations for Sieving Soil and Dust
Samples at Lead Sites for Assessment of Incidental Ingestion. U.S. Environmental Protection Agency,
Office of Superfund Remediation and Technology Innovation, Washington DC. OLEM directive 9200.1-
128. July. Available online at: http://semspub.epa.gov/src/document/HQ/100000133.

U.S. EPA (U.S. Environmental Protection Agency). (2017a) Region 4 Superfund X-Ray Fluorescence Field Operations Guide. U.S. Environmental Protection Agency: Atlanta, GA. SFDGUID-001-R0. July. Available online at: https://www.epa.gov/sites/production/files/2018-04/documents/superfund-field-operations-guide-001-r0_xrf_fog_reg4.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2017b) Standard Operating Procedure for an *In Vitro* Bioaccessibility Assay for Lead and Arsenic in Soil. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9200.2-164. July. Available online at: https://semspub.epa.gov/src/document/HQ/100000153.

U.S. EPA (U.S. Environmental Protection Agency). (2017c) Validation Assessment of the *In Vitro* Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soil and Soil-like Materials at Superfund Sites. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9355.4-29. April. Available online at: http://semspub.epa.gov/src/document/HQ/196751.

U.S. EPA (U.S. Environmental Protection Agency). (2019a) Fact Sheet: Arsenic Relative Bioavailability (RBA) and *In Vitro* Bioaccessibility (IVBA). U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation, Technical Review Workgroup Bioavailability Committee (TRW BAC): Washington DC. December.

U.S. EPA (U.S. Environmental Protection Agency). (2019b) Fact Sheet: Lead Relative Bioavailability (RBA) and *In Vitro* Bioaccessibility (IVBA). U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation, Technical Review Workgroup Bioavailability Committee (TRW BAC): Washington DC. December.

U.S. EPA (U.S. Environmental Protection Agency). (2019c) Guidelines for Human Exposure Assessment. U.S. Environmental Protection Agency, Risk Assessment Forum: Washington, DC. EPA/100/B-19/001. October. Available online at: https://www.epa.gov/sites/production/files/2020-01/documents/guidelines_for_human_exposure_assessment_final2019.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2020) Lead at Superfund Sites: Frequent Questions from Risk Assessors on the Integrated Exposure Uptake Biokinetic (IEUBK) Model. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation, Technical Review Workgroup Lead Committee: Washington DC. January. Available online at: https://www.epa.gov/superfund/lead-superfund-sites-frequent-questions-risk-assessors-integrated-exposure-uptake#Sampling.

APPENDIX A: Guidance for Sample Collection for Estimating an RBA-adjusted Exposure Point Concentration for Soil

The minimum sample number needed to estimate the relative bioavailability (RBA)-adjusted mean soil concentration of a contaminant will depend on the data quality objective (DQO). Data can be collected for the purpose of estimating soil concentrations and/or RBA at a site (estimation study) or for the purpose of supporting decision making (hypothesis testing; U.S. EPA, 2006). An example of an estimation study would be collection of data on soil concentrations or RBA to estimate a mean concentration or RBA and its variance. This might be done to characterize the site or to evaluate heterogeneity in concentration or RBA at the site. An example of hypothesis testing would be collecting data on concentration and RBA, in order to determine whether the mean concentration exceeds an action level (AL). This might be done to decide if an action (e.g., removal, remediation, control) is needed. For estimation studies, sample number predictions are targeted to obtain results that are within acceptance criteria; for example, to achieve a targeted level of confidence in the estimate of the mean or standard deviation (SD). For hypothesis testing, sample number predictions are targeted to obtain acceptable Type 1 (false compliance decision) and Type 2 (false exceedance decision) errors in evaluating validity a null hypothesis (e.g., H_0: concentration exceeds AL) against an alternative hypothesis (H_1: concentration does not exceed AL).

This appendix provides an example of how to estimate sample numbers needed for hypothesis testing; in this case, whether or not the estimated mean adjusted soil concentration for a contaminant exceeds an AL. A similar approach could be used to determine sample numbers needed to support estimation; in this case, the sample numbers would be evaluated in the context of with estimation acceptance criteria, rather than by null and alternative hypotheses related to decision making. The example described in this appendix is for an unspecified contaminant and could be customized for a specific contaminant (e.g., arsenic or lead) by assigning values appropriate for input parameters (e.g., mean and SDs for concentration and RBA, relevant AL). The example evaluates sample number requirements for two types of sampling designs: discrete sampling and incremental composite sampling (ICS). Discrete sampling designs collect individual soil samples and measure concentration in each sample, and RBA in each sample, or in a subset of the samples. Discrete sampling locations are either randomized or gridded, so that the resulting mean (or other statistics) can represent the area being sampled (e.g., decision or exposure unit). ICS designs create multiple composite samples composed of individual randomly located soil samples (referred to as increments). Concentration and RBA are then measured for the composites. Each ICS composite is intended to represent a single estimate of the area mean. Determination of whether discrete or ICS designs are used at a site will depend on the DQO as each offers certain advantages. For example, discrete sampling can provide estimates of variance in the concentration in the area of interest. ICS designs are intended to provide estimates of the area mean and confidence in the mean consistent with estimating an exposure point concentration (EPC) or comparison to a cleanup goal, and do not provide estimates of concentration variance.

Hypothesis to be tested for decision making: We define the null hypothesis (H_0) and alternative hypothesis (H_1) regarding whether the true mean adjusted soil concentration (*adjusted concentration*) is below or above an AL. The AL could be a risk-based concentration or some other soil concentration boundary established for decision making at the site (e.g., removal, remediation, control). The H_0 and H_1 can be defined as follows:

H_0: adjusted mean soil concentration $\geq$ AL

H_1: adjusted mean soil concentration $<$ AL

A Type 1 error occurs if we reject H_0 when it is true; we conclude that the mean adjusted soil concentration is less than the AL, when it is actually greater than or equal to the AL. This is also referred to as a false compliance decision error or false rejection error (U.S. EPA, 2006). A Type 1 error could result in underestimating risk at the site and/or not taking an action when action is needed to reduce risk.

A Type 2 error occurs if we accept H_0 when it is false; we conclude that the mean adjusted soil concentration is above or equal to the AL, when it is actually less than the AL. This is also referred to as a false exceedance decision error or false acceptance error (U.S. EPA, 2006). A Type 2 error could result in overestimating risk at the site and/or taking action at the site when it is not needed to reduce risk.

The objective of a sample number assessment is to identify sample numbers that are expected to satisfy specified requirements for Type 1 and Type 2 error rates. These error rates depend on several factors:

- the difference between the mean adjusted soil concentration and the AL;

- the variability in the soil concentration;

- the mean and variability of the soil RBA; and

- the sampling design used to estimate the mean adjusted soil concentration.

Larger sample numbers will be required to achieve a given error rate when the actual mean adjusted soil concentration is closer to the AL, or when variability (i.e., SD) of the soil concentration or RBA at the site is higher.

Assumptions for calculating sample number: Type 1 and Type 2 error rates were calculated for different numbers of discrete and composite samples having different numbers of contributing increments for RBA and total metals. The calculation method was a Monte Carlo simulation in which concentration and RBA are represented as probability distributions defined by a mean and SD.

A generic example of sample number calculation is presented here. It could be applied to any contaminant, including arsenic or lead, if the appropriate values for the contaminant are used in the calculation. Assumptions in the analysis are as follows:

(1) The underlying distribution of measured concentrations in discrete soil samples at the decision unit is lognormal (the ICS design should collect adequate samples to ensure a normal distribution of the concentrations of multiple composites).

(2) Distribution of measured RBA within a decision unit is normal (e.g., single source of contamination and uniform soil characteristics).

(3) The adjusted soil concentration for the decision unit is:

adjusted soil concentration = soil concentration × soil RBA

(4) For evaluating Type 1 error, we assume that the adjusted mean soil concentration at the decision unit exceeds the AL. For evaluating Type 2 error, we assume that the adjusted mean soil concentration at the decision unit is below the AL.

(5) An acceptable Type 1 error rate is 5% (i.e., the probability of concluding that the adjusted mean soil concentration is less than the AL when it is actually equal to or greater than the AL, is equal to or less than 5%).

(6) An acceptable Type 2 error rate is 20% (i.e., the probability of concluding that the adjusted mean soil concentration is equal to or greater than the AL, when it is actually less than the AL, is equal to or less than 20%). We are typically less concerned about a Type 2 error (overestimating risk) than a Type 1 (underestimating risk).

(7) The ICS design consists of $n = C$ composites collected at the decision unit with each composite consisting of $n = I$ increments, of which, $n = R$ composites are randomly selected for RBA analysis (e.g., *in vitro* bioaccessibility [IVBA]). In this example, we have assumed that the RBA of every composite sample or discrete sample was measured; however, the same approach could be used to estimate sample numbers if RBA was measured in a subset of soil samples.

(8) The estimated mean soil concentration for the decision unit is the mean of measured concentrations of $n = C$ composites.

(9) The estimated mean RBA for the decision unit is based on the mean of measured RBA of $n = R$ randomly selected composites.

(10) Values assumed for soil concentration, AL, and RBA for evaluating Type 1 and Type 2 error rates are presented in Table A-1.

Sample size predictions: Type 1 and Type 2 error rates for various sample designs are presented in Tables A-2 to A-10. These tables provide predictions for a range of variability of soil concentration (coefficient of variation [CV] 0.5, 1.0, 3.0) and RBA variability (CV 0.05, 0.10, 0.30). The magnitude of Type 1 and Type 2 errors depends on the AL and the variability in the soil concentration and soil RBA (represented in the CV), as well as on the sample design. An example is illustrated in Figure A-1, which shows the predicted Type 1 error rate (%) for various numbers of discrete or ICS samples. In the case illustrated in Figure A-1, the SD of the soil concentration was assumed to be 3 times the mean and the SD for RBA was assumed to be 0.3 times the mean. These assumptions represent conditions of relatively high variability in the soil concentration and RBA. An acceptable Type 1 error ($\leq$5%) is predicted for ICS sampling in which 5 ICS composites are collected, with each composite consisting of 100 increments. Figure A-2 shows the prediction for the same sampling designs, at a lower variability in soil concentration (SD equals the mean, or CV=1). In this case, an acceptable Type 1 error is predicted for ICS designs that have 3 composites consisting of 30 increments, or for a discrete sampling design consisting of 100 random samples. Thus, how well a given sampling design performs depends, in part, on the variability in RBA and concentration.

In general, a larger sample size is needed to achieve acceptable Type 1 error when there is a smaller difference between the mean soil concentration and the AL. This is because the Type 1 error also depends on the difference between the actual adjusted mean soil concentration and the AL. For any given sampling design, error rates will increase as the actual mean soil concentration decreases and approaches the AL. This is illustrated in Figures A-3 and A-4, which show the probability of rejecting H_0 (H_0 = adjusted soil concentration is at or above the AL) as the ratio of the mean soil concentration to the AL (mean/AL) changes. Probabilities at soil concentrations that exceed the AL (to the right of the vertical line representing the AL) are Type 1 errors (reject H_0 when it is true). Type 1 errors increase as the mean/AL ratio increases. Figure A-3 shows this relationship for three levels of variation in RBA

(CV 0.05, 0.15, 0.3) and Figure A-4 shows the relationship for three levels of variation in the soil concentration (CV 0.5, 1, 3).

The predictions presented in Tables A-2 to A-10 apply to a sampling design that is intended to estimate the mean adjusted soil concentration for use in risk assessment. For most contaminants (other than lead), the EPC is considered to be the 95% upper confidence limit (95UCL) on the mean. Use of the 95UCL for the EPC will increase the Type 2 error for any given sampling design.

Conclusions:

(1) An objective in sample design is to ensure a Type 1 error (false compliance decision) of ≤5% without exceeding a Type 2 error (false exceedance decision) of 20%.

(2) If the variability in the soil concentration and RBA can be estimated, then Type 1 and Type 2 errors can be predicted for alternative sampling designs. This of course means that some data are available for estimating the soil concentration and RBA variability. Ideally, these data would be for the site; however, data from a surrogate site may have to be used if no site data are available. Note that RBA variability is a function of both site conditions and sampling design.

(3) Type 1 and Type 2 errors will depend on the variability in the soil concentration and RBA, sample numbers, sampling design (discrete or ICS), and how close the actual soil concentration mean is to the AL to be evaluated.

(4) Higher variability in soil concentration or RBA will require a larger number of increments per composite or number of discrete samples to achieve an acceptable Type 1 error rate.

(5) A larger number of increments or discrete samples will be needed if the actual mean soil concentration is closer to the AL, and fewer will be needed if the actual mean concentration is further from the AL.

(6) Tables A-2 to A-10 can be used to find an acceptable sampling design to achieve a Type 1 error of ≤5% for a range of expected variabilities in soil concentration and soil RBA.

Table A-1. Parameter Values for Sample Number Calculation

Parameter	Type 1 Error Assessment	Type 2 Error Assessment
Ratio: mean adjusted soil concentration/AL[a]	1.25[a]	0.75[a]
Soil concentration CV	0.5. 1.0, 3.0[b]	0.5. 1.0, 3.0[b]
Mean soil RBA	0.60	0.60
Soil RBA CV	0.05, 0.15, 0.30[c]	0.05, 0.15, 0.30[c]

[a]Adjusted soil lead = soil concentration × soil RBA.
[b]Soil lead distribution: lognormal (mean, SD).
[c]RBA distribution normal (mean, SD, minimum, maximum), with minimum = 0, maximum = 1.

AL, action level; CV, coefficient of variation (SD/mean); RBA, relative bioavailability; SD, standard deviation

Table A-2. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 3 and RBA CV is 0.3

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
3	0.3	D	30	42	17
3	0.3	D	50	36	14
3	0.3	D	100	26	9.7
3	0.3	3	30	27	10
3	0.3	3	50	20	7.7
3	0.3	3	100	9.4	3.7
3	0.3	4	30	23	8.4
3	0.3	4	50	15	5.6
3	0.3	4	100	5.9	2.3
3	0.3	5	30	20	7.5
3	0.3	5	50	12	4.5
3	0.3	5	100	3.9	1.7

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above or equal to the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above or equal to the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-3. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 3 and RBA CV is 0.15

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
3	0.15	D	30	40	17
3	0.15	D	50	34	15
3	0.15	D	100	24	10
3	0.15	3	30	26	11
3	0.15	3	50	17	8.5
3	0.15	3	100	7.7	3.9
3	0.15	4	30	21	9.0
3	0.15	4	50	14	6.4
3	0.15	4	100	5.1	2.9
3	0.15	5	30	17	8.0
3	0.15	5	50	11	4.9
3	0.15	5	100	3.1	1.6

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-4. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 3 and RBA CV is 0.05

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
3	0.05	D	30	41	17
3	0.05	D	50	33	15
3	0.05	D	100	23	10
3	0.05	3	30	25	11
3	0.05	3	50	18	7.4
3	0.05	3	100	8.1	3.7
3	0.05	4	30	21	9.4
3	0.05	4	50	13	6.2
3	0.05	4	100	5.3	2.7
3	0.05	5	30	17	8.0
3	0.05	5	50	10	4.8
3	0.05	5	100	3.4	1.9

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-5. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 1 and RBA CV is 0.3

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
1	0.3	D	30	15	4.9
1	0.3	D	50	8.1	2.1
1	0.3	D	100	1.9	0.3
1	0.3	3	30	3.0	0.2
1	0.3	3	50	0.6	0.0
1	0.3	3	100	0.0	0.0
1	0.3	4	30	1.4	0.1
1	0.3	4	50	0.2	0.0
1	0.3	4	100	0.0	0.0
1	0.3	5	30	0.7	0.1
1	0.3	5	50	0.1	0.0
1	0.3	5	100	0.0	0.0

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-6. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 1 and RBA CV is 0.15

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
1	0.15	D	30	12	4.9
1	0.15	D	50	5.8	1.8
1	0.15	D	100	1.4	0.2
1	0.15	3	30	2.3	0.3
1	0.15	3	50	0.4	0.0
1	0.15	3	100	0.0	0.0
1	0.15	4	30	0.9	0.1
1	0.15	4	50	0.1	0.0
1	0.15	4	100	0.0	0.0
1	0.15	5	30	0.4	0.0
1	0.15	5	50	0.0	0.0
1	0.15	5	100	0.0	0.0

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-7. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 1 and RBA CV is 0.05

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
1	0.05	D	30	12	4.4
1	0.05	D	50	6.1	1.6
1	0.05	D	100	1.2	0.2
1	0.05	3	30	1.6	0.4
1	0.05	3	50	0.3	0.0
1	0.05	3	100	0.0	0.0
1	0.05	4	30	0.9	0.1
1	0.05	4	50	0.1	0.0
1	0.05	4	100	0.0	0.0
1	0.05	5	30	0.2	0.0
1	0.05	5	50	0.0	0.0
1	0.05	5	100	0.0	0.0

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-8. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 0.5 and RBA CV is 0.3

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
0.5	0.3	D	30	2.3	0.2
0.5	0.3	D	50	0.5	0.0
0.5	0.3	D	100	0.0	0.0
0.5	0.3	3	30	0.0	0.0
0.5	0.3	3	50	0.0	0.0
0.5	0.3	3	100	0.0	0.0
0.5	0.3	4	30	0.0	0.0
0.5	0.3	4	50	0.0	0.0
0.5	0.3	4	100	0.0	0.0
0.5	0.3	5	30	0.0	0.0
0.5	0.3	5	50	0.0	0.0
0.5	0.3	5	100	0.0	0.0

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-9. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 0.5 and RBA CV is 0.15

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
0.5	0.15	D	30	1.1	0.1
0.5	0.15	D	50	0.2	0.0
0.5	0.15	D	100	0.0	0.0
0.5	0.15	3	30	0.0	0.0
0.5	0.15	3	50	0.0	0.0
0.5	0.15	3	100	0.0	0.0
0.5	0.15	4	30	0.0	0.0
0.5	0.15	4	50	0.0	0.0
0.5	0.15	4	100	0.0	0.0
0.5	0.15	5	30	0.0	0.0
0.5	0.15	5	50	0.0	0.0
0.5	0.15	5	100	0.0	0.0

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Table A-10. Error Rates for Discrete or Composite Sample Designs if Soil Concentration CV is 0.5 and RBA CV is 0.05

Concentration CV	RBA CV	Number of ICS Composites	Number of Discrete Samples or ICS Increments	Type 1 Error[a] Rate (%)	Type 2 Error[b] Rate (%)
0.5	0.05	D	30	0.9	0.1
0.5	0.05	D	50	0.1	0.0
0.5	0.05	D	100	0.0	0.0
0.5	0.05	3	30	0.0	0.0
0.5	0.05	3	50	0.0	0.0
0.5	0.05	3	100	0.0	0.0
0.5	0.05	4	30	0.0	0.0
0.5	0.05	4	50	0.0	0.0
0.5	0.05	4	100	0.0	0.0
0.5	0.05	5	30	0.0	0.0
0.5	0.05	5	50	0.0	0.0
0.5	0.05	5	100	0.0	0.0

[a]Type 1 error is an observed mean RBA-adjusted soil concentration that is below the risk-based concentration (AL), when the true RBA-adjusted concentration is above the AL.
[b]Type 2 error is an observed mean RBA-adjusted soil concentration that is above the risk-based concentration (AL), when the true RBA-adjusted concentration is below the AL.

AL, action level; CV, coefficient of variation (SD/mean); D, discrete samples; ICS, incremental composite sample; SD, standard deviation

Figure A-1. Effect of Sample Size on False Negative Error Rates for Discrete or ICS Sampling if the CV for the Soil Concentration is 3 and the CV for RBA is 0.3.

Each bar represents the error rate for a combination a specified number of discrete or ICS increments (30, 50, or 100) and ICS composites (3, 4, or 5), and CV (SD/mean) for concentration and RBA. The horizontal line represents the upper end of the target error rate (≤5%). False negative error (Type 1) was estimated for the condition in which the actual mean RBA-adjusted concentration is 25% above the AL.

Figure A-2. Effect of Sample Size on False Negative Error Rates for Discrete or ICS Sampling if the CV for the Soil Concentration is 1 and the CV for RBA is 0.3.

Each bar represents the error rate for a combination a specified number of discrete or ICS increments (30, 50, or 100) and ICS composites (3, 4, or 5), and CV (SD/mean) for concentration and RBA. The horizontal line represents the upper end of the target error rate (≤5%). False negative error (Type 1) was estimated for the condition in which the actual mean RBA-adjusted concentration is 25% above the action level (AL). False negative error is the probability that sampling would result in an mean RBA-adjusted concentration that is less than the AL, when it is actually 25% greater than the AL.

Figure A-3. Probability of Rejecting Null Hypothesis (H_0 = Adjusted Soil Concentration is Above the Action Level) as the Mean Adjusted Soil Concentration Increases when the CV of RBA is 0.15, 0.30, or 0.50.

Soil concentration CV = 1.0. Sample design is ICS 3 composites composed of 30 increments each. The vertical line represents the AL. Probabilities to the right of the vertical line are Type 1 errors (reject H_0 when it is true).

Figure A-4. Probability of Rejecting Null Hypothesis (H_0 = Adjusted Soil Concentration is Above the Action Level) as the Mean Adjusted Soil Concentration Increases when the CV of Soil Concentration is 0.5, 1, or 3.

RBA CV is 0.15. Sample design is ICS 3 composites composed of 30 increments each. The vertical line represents the AL. Probabilities to the right of the vertical line are Type 1 errors (reject H_0 when it is true).

Reference:

U.S. EPA (U.S. Environmental Protection Agency). (2006) Guidance on Systematic Planning Using the Data Quality Objectives Process. EPA QA/G-4. U.S. Environmental Protection Agency, Office of Environmental Information: Washington, DC. EPA/240/B-06/001. February. Available online at: https://www.epa.gov/sites/production/files/2015-06/documents/g4-final.pdf.

ATTACHMENT A: Frequently Asked Questions on Bioavailability Sampling and Assessment

1. What is the purpose of this guidance?

The purpose of this guidance is to update the 2015 guidance by providing information to assist risk assessors and risk managers in collecting and effectively utilizing data on *in vitro* bioaccessibility (IVBA) and relative bioavailability (RBA) for use in arsenic and lead human health risk assessments. The guidance provides recommendations on the following major topics:

   (1) rationale for collecting RBA data to support human health risk assessment (HHRA);

   (2) application of IVBA and RBA data in HHRA;

   (3) evaluation and analysis of IVBA and RBA data for use in HHRA;

   (4) systematic planning for collection of RBA data; and

   (5) collection and processing of samples for measurement of arsenic and lead IVBA at sites.

2. Where can additional information and assistance on RBA sampling and measurement be obtained?

Additional information and assistance with RBA assessments can be found at the U.S. Environmental Protection Agency (U.S. EPA) Technical Review Workgroup (TRW) Bioavailability Committee (BAC) website (https://www.epa.gov/superfund/soil-bioavailability-superfund-sites-technical-assistance) or can be obtained by contacting the BAC through its email or hotline (bahelp@epa.gov; 1-866-282-8622).

3. What are ABA, RBA, and IVBA?

Absolute bioavailability (ABA): Fraction of an ingested dose of the contaminant (arsenic or lead) that is absorbed from the gastrointestinal tract and enters the blood and tissues.

Relative bioavailability (RBA): Ratio of the ABA of the contaminant in the medium of interest to that of the same contaminant in the medium used to dose the test organism in the oral toxicity studies.

In vitro bioaccessibility (IVBA): Fraction of total amount of arsenic or lead in a soil sample that is soluble in a gastric-like (i.e., low pH) extraction medium.

4. What is the purpose of assessing soil arsenic or lead RBA?

RBA is assessed to increase confidence in human health risk estimates and related risk management decisions at sites. The U.S. EPA recommends that site-specific assessments of soil arsenic and lead RBA be performed for improving the characterization of risk at the site (U.S. EPA, 1989, 2007a, 2007b, 2012b, 2017b).

Estimates of RBA are used to adjust soil action levels (ALs) (or other risk-based levels such as screening levels), exposure point concentrations (EPCs), or oral daily intakes (DIs) when bioavailability in site soil differs from bioavailability in the exposure medium that is the basis for the AL or toxicity value.

Site-specific RBA estimates are also used to adjust soil lead bioavailability parameters in risk assessment models used in site risk assessment (e.g., Integrated Exposure Uptake Biokinetic Model for

Lead in Children [IEUBK model], Adult Lead Model [ALM]) when bioavailability of lead in soil at the site differs from the model default value.

Examples of specific types of adjustments made in risk assessments are described in this guidance.

5. What methods are available for measuring soil RBA?

Various animal models (e.g., monkey, mouse, rabbit, rat, swine) have been used to study oral bioavailability of arsenic or lead in soil. Information on these bioassays and pertinent primary literature can be found in U.S. EPA (2019a, 2019b). Bioassays using these models estimate RBA from measurements of tissue levels or urinary levels in relation to the oral dosage of arsenic or lead.

U.S. EPA has validated an IVBA assay for predicting soil arsenic and lead RBA for use in HHRA and recommends using the IVBA assay for characterizing site-specific soil arsenic or lead RBA (U.S. EPA Method 1340; U.S. EPA, 2017b, 2017c). The assay involves a simulated gastric-phase extraction of arsenic or lead from soil in a relatively simple extraction medium. Information on these bioassays and pertinent primary literature can be found in U.S. EPA (2019a, 2019b).

6. How do you convert IVBA data from the laboratory into estimates of RBA?

RBA is predicted from IVBA using a regression model (U.S. EPA, 2017b). The regression model for converting arsenic IVBA to arsenic RBA is as follows:

$$arsenic\ RBA\ percent = 0.79 \times IVBA\ percent + 3$$

The regression model for converting lead IVBA to lead RBA is as follows:

$$lead\ RBA\ percent = 0.878 \times IVBA\ percent - 2.8$$

Note that, in both of the above equations, RBA and IVBA and the regression intercept are expressed as percents. If the IVBA data from the laboratory are reported as fractions, rather than percents, then the corresponding equation for arsenic RBA, expressed as a fraction, is as follows:

$$arsenic\ RBA\ fraction = 0.79 \times arsenic\ IVBA\ fraction + 0.03$$

and the corresponding equation for the RBA fraction for lead is as follows:

$$lead\ RBA\ fraction = 0.878 \times lead\ IVBA\ fraction - 0.028$$

7. What factors should be considered in choosing between IVBA or *in vivo* RBA assessment methods?

The IVBA assay is a substantially less expensive alternative to an animal bioassay for assessing RBA. The relatively low cost of the IVBA assay compared to an animal bioassay, availability of standard operating procedures (SOPs), and availability of public and commercial laboratories where it can be performed, allows soil samples to be processed more rapidly for the same cost as a single animal bioassay while reducing animal testing. Using the IVBA assay to evaluate multiple soil samples at a site can provide a more thorough assessment of site RBA. However, it is prudent to conduct confirmatory animal RBA bioassays before using an IVBA assay to assess RBA of novel soil types that were not represented in the data used to validate the IVBA assay. These may include soils with chemical and physical characteristics outside the domain of soils used to develop and validate the IVBA assay. It may also include soils that have received treatments with amending agents that alter mobility or solubility of

arsenic or lead. For example, IVBA methods have not been validated for predicting RBA of lead in soils amended with high levels of phosphate to reduce lead bioavailability. Additional information on limitations of the IVBA assays can be found in the technical literature available on the U.S. EPA TRW BAC website or can be obtained by contacting the BAC through its email or hotline (bahelp@epa.gov; 1-866-282-8622).

8. How can RBA be used to adjust the lead bioavailability parameter in the IEUBK model?

The IEUBK model includes a parameter that is used in the calculation of the absorption fraction percent for soil lead (AFP_{soil}) (U.S. EPA, 1994). Users adjust this parameter for RBA when site-specific RBA is to be included in the IEUBK model prediction of the child blood lead distribution. The adjustment is as follows:

$$adjusted\ AFP_{soil} = RBA\ fraction \times 50$$

where RBA is expressed as a fraction, and 50 is the IEUBK model assumption for the absorption fraction percent of lead in drinking water (AFP_{water}). The IEUBK model includes a default value for AFP_{soil} of 0.3, which is equivalent to a default RBA fraction of 0.6 multiplied by the AFP_{water} (50%). A detailed explanation of how to make an RBA adjustment of the IEUBK model is provided in Attachment B (*Calculation of IEUBK Model and Adult Lead Methodology (ALM) Absorption Fraction Parameters from IVBA Results of EPA Method 1340*). An example of an assessment of RBA for the purpose of adjusting the soil absorption parameter in the IEUBK model is provided in Attachment G (*Relative Bioavailability Adjustment of Absorption Fraction Parameters in the Integrated Exposure Biokinetic Model for Lead in Children and Adult Lead Methodology: Cherokee County Railroad Site Case Study*)

9. How can RBA be used to adjust the lead bioavailability parameter in the Adult Lead Methodology (ALM)?

The ALM includes a parameter that represents the absorption fraction of ingested lead in soil and dust lead. Users adjust this parameter for RBA when site-specific RBA is to be included in the ALM prediction of the fetal blood lead distribution. The adjustment is as follows:

$$adjusted\ AF_{S+D} + dust = RBA\ fraction \times 0.2$$

where AF_{S+D} is the ALM parameter for the gastrointestinal absorption fraction of lead in soil and dust, RBA is expressed as a fraction, and 0.2 is the ALM default assumption for the absorption fraction of soluble lead (U.S. EPA, 2003c). A detailed explanation of the adjustment of how to make an RBA adjustment of the ALM is provided in Attachment B (*Calculation of IEUBK Model and Adult Lead Methodology (ALM) Absorption Fraction Parameters from IVBA Results of EPA Method 1340*). An example of an RBA assessment of RBA for the purpose of adjusting the soil absorption parameter in the IEUBK model is provided in Attachment G (*Relative Bioavailability Adjustment of Absorption Fraction Parameters in the Integrated Exposure Biokinetic Model for Lead in Children and Adult Lead Methodology: Cherokee County Railroad Site Case Study*).

10. How can RBA be used to adjust a soil exposure point concentration (EPC)?

The EPC should represent the average exposure experienced by the receptor within the exposure unit or decision unit (U.S. EPA, 2002b). For contaminants other than lead, removal and remedial decisions are often made at sites based, in part, on a calculation of the risk from the EPC using a toxicity value (e.g., oral reference dose [RfD], oral cancer slope factor), which represents an upper limit of the DI of the contaminant in soil that poses negligible risk. The EPC can be adjusted to account for differences between the bioavailability of the contaminant in soil and the bioavailability assumed in the derivation of the toxicity value or screening level. This adjustment facilitates comparisons of EPCs to screening levels

that are based on specific RBA assumptions. In lead risk assessments, RBA-adjusted EPCs can be used in batch file processing of input data for the IEUBK model. The adjustment is as follows:

$$adjusted\ EPC = EPC \times RBA\ fraction$$

where RBA is expressed as a fraction. An example of an assessment of RBA for the purpose of adjusting an EPC for arsenic and lead is provided in Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study*).

11. How can RBA be used to adjust a soil contaminant daily oral intake?

For contaminants other than lead, removal and remedial decisions are made at sites based, in part, on comparison of the oral DI of a contaminant to a toxicity value such as a chronic oral RfD, which represents an upper limit of the contaminant intake soil that poses negligible risk. The DI for arsenic can be adjusted to account for differences between the bioavailability of the contaminant in soil and the bioavailability assumed in the derivation of the RfD. The adjustment is as follows:

$$adjusted\ DI = DI \times RBA\ fraction$$

where RBA is expressed as a fraction. An example of an assessment of RBA for the purpose of adjusting an oral DI for soil arsenic is provided in Attachment D (*Bioavailability Adjustment of Daily Oral Intake of Arsenic in a Baseline Human Health Risk Assessment: A Case Study*). An example of how to adjust a time-weighted soil lead concentration is provided in Attachment H (*Relative Bioavailability Adjustment of Soil Lead Exposure Point Concentrations for a Time-Weighted Exposure to Soil*).

12. How can RBA be used to adjust a soil arsenic or lead risk-based screening level or action level (AL)?

At sites where removal and remedial decisions are made based, in part, on comparison of the EPC to an AL or risk-based concentration or screening level, the AL can be adjusted to account for differences between the bioavailability of the contaminant in soil and the bioavailability assumed in the derivation of the AL. The adjustment should be made to the AL or to the EPC (see Section 5.3), but not to both. The exact adjustment to be made will depend on what assumptions about RBA are incorporated into the AL. For example, if a soil AL for arsenic has been derived assuming an RBA for arsenic of 1.0, then a site-specific RBA adjustment of the AL must be a value relative to 1. For example:

$$adjusted\ AL = AL \times 1.0/RBA\ fraction$$

where RBA expressed as a fraction. An example of adjustment of a soil AL for arsenic is presented in Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*). Lead ALs derived from the IEUBK model that assume that the default model RBA value of 0.6 (absorption fraction for lead in soil = 0.3, absorption fraction for lead in drinking water = 0.5), would be adjusted as follows:

$$adjusted\ AL = AL \times 0.6/RBA\ fraction$$

An example for the adjustment of a risk-based concentration for lead is provided in Attachment F (*Relative Bioavailability Adjustment of a Risk-Based Concentration for Lead: A Case Study – Adjusting RBA in the IEUBK Model and ALM*).

13. What is a soil RBA data quality objective?

A data quality objective (DQO) process is used to establish performance or acceptance criteria, which serve as the basis for designing a plan for collecting data of sufficient quality and quantity to support site assessment and remedial decision making. As with planning any environmental sampling, DQOs should be developed for RBA data collection. See the *Guidance on Systematic Planning Using the Data Quality Objectives Process* (U.S. EPA, 2006) for further discussion. The development of DQOs is a 7-step process:

    (1) state the problem;

    (2) identify the goal of the study;

    (3) identify information inputs;

    (4) define the boundaries (in space and time) of the study;

    (5) develop the analytical approach;

    (6) specify the performance criteria; and

    (7) develop a detailed plan for obtaining the data.

The final step of the DQO process is to develop a sampling and analysis plan. This plan should consider potential soil exposure pathways for the site and any existing site data. If existing sampling data are available for a site, the information could assist in understanding the variability of data at the site and in planning a representative sampling design. Samples collected to assess RBA and total metal concentrations should be representative of the bioavailability throughout the area of exposure (i.e., the exposure unit). The *Guidance on Choosing a Sampling Design for Environmental Data Collection for Use in Developing a Quality Assurance Project Plan* is a useful resource for selecting a design to meet the project DQOs and provide representative data (U.S. EPA, 2002a). An example of application of DQOs to RBA assessment is presented in Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study*). Consultation with a qualified statistician who has experience with sampling design is recommended.

14. What factors should be considered in designing a retrospective RBA assessment based on archived soils samples?

Retrospective RBA assessments are sometimes undertaken at sites based on RBA measurements made on archived soils collected for some other purpose (e.g., discovery, preliminary site characterizations, assessments to support removal decisions). In these instances, the original sampling design may not have considered DQOs for characterizing RBA. Therefore, development of a DQO for RBA assessment based on the archived soils is advised so that an appropriate approach to selecting soils for RBA measurement may be developed. For example, if the DQO is to estimate a site-wide RBA value, then consideration should be given to whether or not the archived soils actually provide a representative sample of RBA at the site. If not, sources of sampling bias should be identified and incorporated into the approach to selecting soils for RBA measurements. If these biases cannot be controlled with the method used to select samples, then they should be considered in the interpretation of the results and in any decisions that are made based on the results. In the absence of a DQO and appropriate sampling design, RBA assessments would be based on a "convenience sample" (e.g., random sample of the archive), rather than on a statistical sample of the site. Use of convenience samples to estimate a site-wide or area-wide RBA introduces larger uncertainty into the RBA estimate. For this reason, the selection of the statistic to represent the site or area RBA may need to recognize greater uncertainty in the mean. For example,

rather than using a mean or 95% upper confidence limit (95UCL) of the mean, an upper percentile or maximum might be considered to represent RBA at the site. An example of a retrospective RBA assessment at a site based on measurement of the RBA using archived samples is provided in Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*).

15. How do you evaluate data adequacy in RBA assessments?

Evaluation of adequacy of RBA data begins with a thorough evaluation of the data against the quality control limits for the methods used to collect the data. Quality control criteria of arsenic and lead IVBA assays can be found in the SOPs for the assay (U.S. EPA, 2017b). Quality evaluation of RBA data also includes evaluation of the implementation of sample collection methods to determine whether or not the sample design was followed and, if not, the causes, effects, and implications of deviations from the plan. Provided that quality control requirements for sampling and analysis have been achieved, adequacy of the RBA data should be evaluated against the DQO for RBA at the site. The DQO should specify performance and acceptance criteria of the data. More information on DQOs and performance criteria can be found in the *Guidance on Systematic Planning Using the Data Quality Objectives Process* (U.S. EPA, 2006). For DQOs that test hypotheses such as, "is the EPC greater than an AL," the collected data should result in acceptable false compliance decision error (Type 1) and false exceedance decision error (Type 2) probabilities. A false compliance decision error occurs if it is concluded that the EPC is less than the AL, when it is actually greater than the AL. This outcome is also referred to as a false rejection error (U.S. EPA, 2006). A false compliance decision error could result in underestimating risk at the site and/or not taking an action when action is needed to reduce risk. A false exceedance decision error occurs if it is concluded that the EPC exceeds the AL, when it is actually less than the AL. This outcome is also referred to as a false acceptance error (U.S. EPA, 2006). A false exceedance decision error could result in overestimating risk at the site and/or taking action at the site to reduce risk when no action is needed. An example of how to estimate decision error probabilities that rely on estimates of RBA-adjusted EPCs is provided in Appendix A (*Guidance for Sample Collection for Estimating an RBA-adjusted Exposure Point Concentration for Soil*). The example is presented from the perspective of systematic planning for data collection; however, the data collected can be analyzed using the same methods to evaluate whether data collected were within acceptable limits of decision error.

16. What RBA statistic should be used to represent an RBA for a decision unit?

Selection of a statistic to represent the RBA for a decision unit will depend on the DQO established for the decision. If the RBA is to be used to adjust the EPC for the decision unit (i.e., adjusted EPC = EPC × RBA), the statistic selected to represent the RBA should be consistent with the definition of the EPC [see Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study*)]. Often, in HHRA, the decision unit represents an exposure unit, within which the receptor has an equal probability of being exposed to soil contaminants anywhere within the decision unit. In this context, the EPC should be the average concentration in the decision unit, estimated as the arithmetic mean or the 95UCL of the mean, from a representative set of soil samples collected from the decision unit (U.S. EPA, 1989, 2002b, 2019c). If the EPC is intended to represent the average exposure concentration at the decision unit, then, consistent with the EPC representing the average exposure, the RBA-adjusted exposure should also represent the average and the statistic to be used to represent the RBA should be the mean or 95UCL of the mean.

The RBA may also be used to adjust the AL applied to evaluating the decisions such as whether or not to remediate at the decision unit [e.g., adjusted AL = AL/RBA; Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*)]. This adjustment, conceptually, also represents an adjustment of the EPC, in that, an upward adjustment of the AL implies that the EPC can be higher without exceeding the AL. Therefore, the adjustment of the AL should also be

consistent with the definition of the EPC. If the EPC is intended to represent the average exposure concentration at the decision unit, then the mean or 95UCL should be selected to represent the RBA.

In some circumstances, it may be prudent to consider statistics other than the mean (or 95UCL) to represent the RBA [see Attachment E (*Retrospective Relative Bioavailability Assessment in Support of a Removal Decision: A Case Study*)]. For example, heterogeneity in RBA within the decision unit, if detected from sampling or inferred from other information about sources of contamination, may prompt consideration of a percentile to represent the RBA. The selection of the percentile will depend on the observed distribution of RBA within the decision unit. The RBA distribution can be estimated from a properly designed discrete sampling plan. In selecting a percentile rather than a mean to represent the RBA, the resulting adjusted EPC or AL will no longer represent the average adjusted exposure. This bias may be warranted on the basis of ensuring that risk is not underestimated at a decision unit in which there is high variability in RBA. Selection of an upper percentile to represent the RBA at the decision unit will decrease false compliance decision error and increase false exceedance decision error [see Appendix A (*Guidance for Sample Collection for Estimating an RBA-adjusted Exposure Point Concentration for Soil*), for further explanation of decision errors].

17. How would you estimate a site-wide RBA from RBA data on multiple decision units?
A site-wide RBA may be estimated to simplify risk assessment calculations at sites where RBA is found be (or is assumed to be) homogenous across decision units. The method used to estimate a site-wide RBA will depend on the DQO and the conceptual site model (i.e., how well decision units represent the site), as well as the distribution of observed RBAs in the decision unit.

Use of a site-wide RBA to adjust decision EPCs or decision unit ALs: Often, in HHRA, the decision unit represents an exposure unit, within which the receptor has an equal probability of being exposed to soil contaminants anywhere within the decision unit. In this context, the EPC representing exposure within the decision unit should be the average concentration in the decision unit, estimated as the arithmetic mean or the 95UCL of the mean. The assumption of equal probability of exposure may not apply across decision units. If it did, the entire site could be considered a single decision unit. If exposure cannot be assumed to be random across the site, then use of a site-wide RBA to adjust decision unit EPCs or ALs is not advised, and these adjustments should be made at the decision unit level. If a site-wide RBA is to be used to assess risk at the decision unit level, and exposure is not random across the site, then some form of spatial or activity weighting of the decision units should be considered in the calculation of a site-wide RBA. However, it must be kept in mind that a weighted or unweighted estimate of a site-wide RBA (e.g., weighted mean) may over- or underestimate RBA at any given decision unit and, as a result, there will be lower confidence in the resulting adjusted EPC or adjusted AL for the decision unit if adjusted by a site-wide RBA. For this reason, consideration should be given in decision unit-level assessments for measuring RBA at each decision unit being assessed. If only a subset of decision units is assessed for RBA, then the DQO should address the following: (1) plan for selecting decision units for RBA measurement that ensures that resulting data can be used to predict RBAs at these decision units that are not selected for RBA measurement and (2) statistic to be used to represent the RBA at decision units not selected for measurement of RBA [see Attachment C (*Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study]*).

Use of a site-wide RBA to characterize RBA variability at the site: Assessment of site-wide variability in RBA can support decisions to assess RBA at the decision unit level. It may also reveal heterogeneity in RBA across the site that may be related to multiple sources of contamination with materials that have different RBA. If the objective is to understand variability in RBA at the site, then decision unit RBAs can be analyzed in a variety of ways, including probability plots and spatial

distribution plots. The outcome of these analyses will determine how the site-wide RBA is to be estimated (e.g., unweighted or spatially weighted statistics).

18. How many samples should be collected to estimate a soil RBA for a decision unit?
The minimum sample number needed to estimate the RBA-adjusted mean soil concentration of a contaminant will depend on the DQO. Data can be collected for the purpose of estimating soil concentrations and/or RBA at a site (estimation study) or for the purpose of supporting decision making (hypothesis testing; U.S. EPA, 2006). The number of samples needed will depend on numerous factors, which may need to be assumed before the study is undertaken. These factors include concentration and RBA variability at the site, the difference between the average soil concentration and the AL (or risk-based concentration, screening level, removal management level, etc.) that is to inform the decision, and the sampling design (e.g., discrete, incremental composite sampling [ICS]). An example of how to estimate sample numbers needed for decision making that relies on estimates of RBA-adjusted EPCs is provided in Appendix A (*Guidance for Sample Collection for Estimating an RBA-adjusted Exposure Point Concentration for Soil*).

19. How can the conceptual site model be used to inform RBA sampling?
Selection of an appropriate sampling design and sample numbers used to assess RBA at a site will depend, in part, on the RBA variability at the site. Often, in developing sampling design to support a DQO, accurate information of RBA variability may not be available (e.g., if site was not previously sampled) and would have to be assumed. These assumptions can be informed by the conceptual site model, which may identify factors that could contribute variability of RBA across the site. Examples of these factor include:

- Would the source(s) of contamination be expected to result in low or high variability in RBA? For example, multiple sources may release different forms of arsenic or lead, which could have different RBAs, depending on the initial source of contamination, timing of release, and environmental conditions that affect leaching and redistribution of the contamination and mixing with background sources.

- Does the soil or sediment geochemistry vary across the site? For example, local and regional variability in soil characteristics could contribute to RBA variability across the site.

- What are the expected soil concentrations? For example, decisions about contaminant concentrations that are more than 100 times the AL may not be appreciably affected by RBA assessments.

20. How can information on soil concentrations be used to select samples for RBA measurement?
RBA of soil arsenic and lead can be expected to range from 0 to 100%. Over the RBA range of 1 to 100%, adjustments of the EPC or AL to account for RBA will be less than a factor of 100, and decisions about contaminant concentrations (removal, remediation, control) that are more than 100 times the AL may not be appreciably affected by RBA assessments.

Large variations in concentrations across the site may also be indicative of multiple sources of contamination and, possibly, associated variation in RBA. This information may be useful for developing sampling designs in the DQO process. However, selection of soils for RBA assessment based on contaminant concentrations should be done in a manner that avoids biasing the data. The DQO planning process should be used to ensure that the resulting data can satisfy the DQO. For example, if the DQO is to estimate a site-wide RBA, selection of soils based on concentration may bias the site-wide estimate if some areas are sampled much less densely than others. This consideration is particularly important if the

RBA results are to be used to predict RBA based on concentrations at locations where RBA was not measured.

An alternative to selection of soils for RBA assessment based on concentration is to select a random sample of soils and then analyze the data for RBA variance attributable to concentration (e.g., analysis of variance, regression modeling). Often, this approach may be preferable, given the relatively low additional expense of IVBA assays, the importance of understanding variability, and the need for samples to be representative (i.e., in addition to the expense of contaminant concentration measurements).

21. How can information on mineralogy and speciation be used to select samples and methods for RBA measurement?
Information on mineralogy and speciation can be useful to explain RBA variability at the site. This information may be useful for developing sampling designs in the DQO process. Speciation of soil metals is a technically complex and is often applied to a small subset of samples for the purpose of explaining observed RBA rather than for predicting RBA in advance of measurements. For example, unusual or unexpected RBA values may be followed up with speciation measurements to better understand why the RBA values were observed or to improve predictions of RBA from IVBA.

22. What depth should be sampled for RBA?
The appropriate sampling depth for a site will depend on the expected exposure pathways for a site. For most scenarios involving exposure to contaminated surface soil, U.S. EPA recommends a sampling depth of the top 0–1 inches of soil below organic litter and sod for lead exposure analysis (U.S. EPA, 2020). With this shallow sample depth, obtaining sufficient sample mass for discrete samples may require collecting a larger mass of soil than is typical, especially if the material is particularly coarse. ICS can provide larger masses for shallow samples. If there are other exposure scenarios for a site, alternative sampling depth intervals that would represent these scenarios should be collected

23. How should the samples be prepared for delivery to the laboratory?
A detailed description of recommendations on preparation of field samples is provided in Section 5 of the *Guidance for Sample Collection for In Vitro Bioaccessibility Assay for Arsenic and Lead in Soil*. The guidance includes recommendations on sample containers and field sieving.

References:

U.S. EPA (U.S. Environmental Protection Agency). (1989) Risk Assessment Guidance for Superfund Volume 1 Human Health Evaluation Manual (Part A). U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. EPA/540/1-80/0023. December. Available online at: https://www.epa.gov/risk/risk-assessment-guidance-superfund-rags-part.

U.S. EPA (U.S. Environmental Protection Agency). (1994) Technical Support Document for the Integrated Exposure Uptake Biokinetic Model for Lead in Children (v0.99d). U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. EPA 9285.7-22. December. Available online at:
https://www.epa.gov/superfund/lead-superfund-sites-software-and-users-manuals.

U.S. EPA (U.S. Environmental Protection Agency). (2002a) Guidance on Choosing a Sampling Design for Environmental Data Collection for Use in Developing a Quality Assurance Project Plan. U.S. Environmental Protection Agency, Office of Environmental Information. Washington, DC. EPA QA/G-5S. EPA/240/R-02/005. Available online at: https://www.epa.gov/sites/production/files/2015-06/documents/g5s-final.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2002b) Calculating Upper confidence Limit for Exposure Point Concentrations at Hazardous Waste Sites. U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. OSWER 9285.6-10. July. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100CYCE.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2003c) Recommendations of the Technical Review Workgroup for Lead for an Approach to Assessing Risks Associated with Adult Exposures to Lead in Soil. U.S. Environmental Protection Agency: Washington, DC. EPA-540-R-03-001, OSWER Directive #9385.7-54. December. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100A16H.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2006) Guidance on Systematic Planning Using the Data Quality Objectives Process. EPA QA/G-4. U.S. Environmental Protection Agency, Office of Environmental Information: Washington, DC. EPA/240/B-06/001. February. Available online at: https://www.epa.gov/sites/production/files/2015-06/documents/g4-final.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2007a) SW-846. Chapter Three – Inorganic Analytes. Revision 4. U.S. Environmental Protection Agency, Office of Resource Conservation and Recovery: Washington, DC. February. Available online at: https://www.epa.gov/sites/production/files/2015-10/documents/chap3_1.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2007b) Method 6200 – Field Portable X-ray Fluorescence Spectrometry for the Determination of Elemental Concentrations in Soil and Sediment. SW- 846, Update VI. Revision 0. U.S. Environmental Protection Agency, Office of Resource Conservation and Recovery: Washington, DC. February. Available online at: https://www.epa.gov/sites/production/files/2015-12/documents/6200.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2012b) Compilation and Review of Data for Relative Bioavailability of Arsenic in Soil and Recommendations for Default Value for Relative Bioavailability. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. EPA 9200.1-113. December. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100FKWO.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2017b) Standard Operating Procedure for an *In Vitro* Bioaccessibility Assay for Lead and Arsenic in Soil. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9200.2-164. July. Available online at: https://semspub.epa.gov/src/document/HQ/100000153.

U.S. EPA (U.S. Environmental Protection Agency). (2017c) Validation Assessment of the *In Vitro* Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soil and Soil-like Materials at Superfund Sites. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9355.4-29. April. Available online at: http://semspub.epa.gov/src/document/HQ/196751.

U.S. EPA (U.S. Environmental Protection Agency). (2019a) Fact Sheet: Arsenic Relative Bioavailability (RBA) and *In Vitro* Bioaccessibility (IVBA). U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation, Technical Review Workgroup Bioavailability Committee (TRW BAC): Washington DC. December.

U.S. EPA (U.S. Environmental Protection Agency). (2019b) Fact Sheet: Lead Relative Bioavailability (RBA) and *In Vitro* Bioaccessibility (IVBA). U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation, Technical Review Workgroup Bioavailability Committee (TRW BAC): Washington DC. December.

U.S. EPA (U.S. Environmental Protection Agency). (2019c) Guidelines for Human Exposure Assessment. U.S. Environmental Protection Agency, Risk Assessment Forum: Washington, DC. EPA/100/B-19/001. October. Available online at: https://www.epa.gov/sites/production/files/2020-01/documents/guidelines_for_human_exposure_assessment_final2019.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2020) Lead at Superfund Sites: Frequent Questions from Risk Assessors on the Integrated Exposure Uptake Biokinetic (IEUBK) Model. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation, Technical Review Workgroup Lead Committee: Washington DC. January. Available online at: https://www.epa.gov/superfund/lead-superfund-sites-frequent-questions-risk-assessors-integrated-exposure-uptake#Sampling.

ATTACHMENT B: Calculation of IEUBK Model and Adult Lead Methodology (ALM) Absorption Fraction Parameter from IVBA Results of EPA Method 1340

The Integrated Exposure Uptake Biokinetic Model for Lead in Children (IEUBK model) allows the user to specify a site-specific value for the parameter absorption fraction percent for soil lead (AFP_{soil}). This value is entered in the *GI Values/Bioavailability Information* menu (*GI/Bio*) of the IEUBK model (Figure B-1). The value for AFP_{soil} can be estimated from *in vitro* bioaccessibility (IVBA) of site soil samples measured using U.S. Environmental Protection Agency (U.S. EPA) Method 1340, which provides predictions of relative bioavailability (RBA). The procedure for converting IVBA into AFP_{soil} is described below.

The initial step in the process is to convert laboratory data on IVBA to corresponding values for RBA by applying the Method 1340 regression model relating RBA and IVBA. The exact calculation to be used will depend on the data that will be generated by the laboratory that runs Method 1340. The resulting value for RBA to be assumed in the risk assessment is then converted to a corresponding value for AFP_{soil} in the IEUBK model.

Four cases of different presentations of laboratory IVBA data are presented below.

(1) If the laboratory reports IVBA as a fraction, rather than as a percent, then the calculation of AFP_{soil} is as follows:

$$RBA\ fraction = IVBA\ fraction \times 0.878 - 0.028 \qquad \text{Eq. (B-1a)}$$

$$AFP_{soil} = RBA\ fraction \times AFP_{water} \qquad \text{Eq. (B-1b)}$$

where RBA is expressed as a fraction; 0.878 and 0.028 are the regression slope and intercept, respectively, for the relationship (linear regression) between IVBA and RBA for lead in soil; and the absorption fraction percent of lead in drinking water (AFP_{water}) is the default value (50%) from the IEUBK model for soluble lead.

(2) If the laboratory reports IVBA in units of percent, then the calculation of AFP_{soil} is as follows:

$$RBA\ fraction = IVBA\ percent/100 \times 0.878 - 0.028 \qquad \text{Eq. (B-2b)}$$

$$AFP_{soil} = RBA\ fraction \times AFP_{water} \qquad \text{Eq. (B-2b)}$$

(3) If the laboratory reports RBA rather than IVBA, and reports RBA as a fraction, then the calculation of AFP_{soil} is as follows:

$$AFP_{soil} = RBA\ fraction \times AFP_{water} \qquad \text{Eq. (B-3)}$$

(4) If the laboratory reports RBA rather than IVBA, and reports RBA as a percent, then the calculation of AFP_{soil} is as follows:

$$AFP_{soil} = RBA\ percent/100 \times AFP_{water} \qquad \text{Eq. (B-4)}$$

Examples:

	Equations	Measured IVBA	Predicted RBA	IEUBK Absorption Fraction Percent
Case 1	B-1a,b	0.45	0.37	18%
Case 2	B-2a,b	50%	0.41	21%
Case 3	B-3	--	60%	30%
Case 4	B-4	--	0.50	25%

The corresponding absorption parameter in the ALM is the absorption fraction for soil and dust (AF_{S+D}), which sets the value for the fraction of ingested soil lead that is absorbed into blood (equivalent to soil lead ABA). The default value for AF_{S+D} in the ALM is 0.12 (12%), which was based on an RBA for soil lead of 60% and an absorption fraction for soluble lead in adults of 20% (i.e., 12/20 = 0.6; U.S. EPA, 2003c). A site-specific value for AF_{S+D} can be calculated from measurements of soil RBA as follows:

$$AF_{S+D} = RBA\% / 100 \times 0.20$$

Examples:

	Equations	Measured IVBA	Predicted RBA	ALM Absorption Fraction
Case 1	B-1a,b	0.45	0.37	7.4%
Case 2	B-2a,b	50%	0.41	8.2%
Case 3	B-3	--	60%	12%
Case 4	B-4	--	0.50	10%

Figure B-1. Default Parameters for Absorption Fraction Percent in the IEUBK Model.

Reference:

U.S. EPA (U.S. Environmental Protection Agency). (2003c) Recommendations of the Technical Review Workgroup for Lead for an Approach to Assessing Risks Associated with Adult Exposures to Lead in Soil. EPA-540-R-03-001, OSWER Directive #9385.7-54. December. Available online at: https://www.epa.gov/superfund/lead-superfund-sites-software-and-users-manuals.

ATTACHMENT C: Relative Bioavailability Adjustment of Decision Unit Exposure Point Concentrations for Arsenic and Lead: Upper Columbia River Case Study

Site description: As part of human health risk assessment (HHRA), residential soils and beach sediments were sampled for arsenic and lead concentrations and relative bioavailability (RBA) at 162 decision units, along a 25-mile stretch of the Upper Columbia River (Integral, 2014; SRC, 2014; TAI, 2016; U.S. EPA. 2017a). Contamination was thought to have occurred predominantly by aerial deposition from local smelter operations, historic dumping of smelter waste into the river, and possibly by other local sources.

Data Quality Objective (DQO): The complete DQO for sampling can be found in the Quality Assurance Project Plans (QAPPs) for the residential soil studies (SRC, 2014; TAI, 2016). An objective of the study was to collect data that would provide a basis for adjusting EPC for arsenic and lead at each decision unit for RBA.

Sampling approach: Sampling locations for the residential soil studies were decision units varying in size from approximately <1 to 5 acres. The sampling design was incremental composite sampling (ICS). For approximately 40% of residential decision units, 3 composites of 30 increments each were collected. At residential properties in which there were multiple decision units of the same type (e.g., more than one garden), three incremental composite (IC) samples were collected at one decision unit and single composites (30 increments) were collected at the other decision units of the same type on the same property. Sampling depths were tilled depth for gardens (generally 0–12 inches), 0–3 inches for disturbed areas (e.g., animal activity areas), 0–1 inch for other residential soils, and 0–6 inches for beaches. Residential sampling was conducted in two time periods (referred to as 2014 and 2016), which covered overlapping areas along the river (Figures C-1 and C-2). In the 2014 sampling, out of 201 decision units sampled (not including driplines), decision units were selected for *in vitro* bioaccessibility (IVBA) measurement if the concentration in a composite sample exceeded either 20 mg arsenic/kg or 100 mg lead/kg. One IC sample was selected for IVBA analysis from each eligible decision unit. In addition, all IC samples with relative percent differences for lead or arsenic concentration that were >30% were selected for IVBA measurement. This resulted in a total of 114 decision units (57%) being characterized for IVBA. In the 2016 sampling, a random sample of 20% of decision units that met the above concentration criteria were selected for IVBA measurement, resulting in a total of 41 decision units (9%) being characterized for IVBA. As in the 2014 sampling, IVBA was measured in a single IC sample from each decision unit. Concentrations and IVBA (U.S. EPA, 2017b, 2017c, 2017d) were measured in residential soil samples that were sieved to <150 µm; beach sediment samples were sieved to <250 µm (U.S. EPA, 2017a). Altogether, IVBA was assayed on a total of 138 residential soil decision units and 23 beach decision units, representing approximately 20% of all residential decision units and approximately 75% of all beach decision units.

RBA adjustments of arsenic and lead concentrations: For each decision unit with IVBA data, an RBA-adjusted soil lead concentration was calculated using the following equations (U.S. EPA, 2017f):

$$RBA\% = (0.878 \times IVBA\% - 2.8)$$

$$RBA\text{-}adjusted\ lead\ concentration = RBA/0.6 \times measured\ lead\ concentration$$

where IVBA is in percent format (i.e., not as a fraction), 0.6 is the default soil RBA in the Integrated Exposure Uptake Biokinetic Model for Lead in Children (IEUBK model) (0.6 = 0.3/0.5), and the measured lead concentration is based on the IC sample result (or average, if replicate IC samples were collected).

RBA-adjusted soil arsenic concentration was calculated using the following equations (U.S. EPA, 2017f):

$$RBA\% = (0.79 \times IVBA\% + 3)$$

$$RBA\text{-adjusted arsenic concentration} = RBA \times \text{measured arsenic concentration}$$

where IVBA is in percent format (i.e., not as a fraction).

RBA results from 2014 and 2016: Mean RBA for decision units sampled in 2016 were significantly lower for both lead and arsenic than the means for decision units sampled in 2014 (t-test, $p<0.001$). The difference between the mean arsenic RBA in residential soils measured at decision units sampled in 2014 ($n = 100$) and 2016 ($n = 38$) was 11.6 (95% confidence interval [CI]: 9, 14); and the difference between the 2014 and 2016 mean lead RBA was 12.6 (95% CI: 8, 17).

Several factors may have contributed to the differences in the RBA means from the 2014 and 2016 sampling events, including the chemical form of arsenic or lead in the soil as well as physical-chemical characteristics of arsenic- or lead-bearing soil particles in soils. The 2016 samples were collected, in general, further to the south than the 2014 samples and further from lead and arsenic smelter emission sources located in the northern stretches of the river (Figures C-1 and C-2). Given that the above factors may have contributed to the variability in RBA, area mean RBAs were estimated for soils and beaches located within or outside of the 2014 soil study boundary (Tables C-1 and C-2).

Application of the IVBA information for HHRA: When decision unit-specific IVBA information was available, it was used to adjust RBA for that specific decision unit. For those decision units where IVBA was measured, the sample of RBAs estimated from IVBA was used to assign RBA values to decision units, as follows: decision units located within 2014 boundary were assigned the mean measured RBA of all decision units within the 2014 boundary and decision units outside of the 2014 boundary were assigned the mean measured RBA of all decision units outside the 2014 boundary (Tables C-1 and C-2).

Table C-1. Summary Statistics for Decision Unit RBAs (Excluding Beaches)					
	N	**Mean**	**SD**	**SE**	**CV**
Lead RBA %					
Outside 2014 Boundary	32	50.5	13.6	2.4	0.27
Inside 2014 Boundary	107	63.9	7.6	0.7	0.12
Arsenic RBA %					
Outside 2014 Boundary	32	16.4	6.6	1.2	0.41
Inside 2014 Boundary	107	27.6	7.4	0.7	0.27

CV, coefficient of variation (SD/mean); RBA, relative bioavailability; SD, standard deviation; SE, standard error

Table C-2. Summary Statistics for Beach Decision Unit RBAs					
	N	Mean	SD	SE	CV
Lead RBA %					
Outside 2014 Boundary	5	50.2	9.7	4.3	0.19
Inside 2014 Boundary	18	56.8	5.8	1.4	0.10
Arsenic RBA %					
Outside 2014 Boundary	5	21.2	6.2	2.8	0.29
Inside 2014 Boundary	18	30.0	5.1	1.2	0.17

CV, coefficient of variation (SD/mean); RBA, relative bioavailability; SD, standard deviation; SE, standard error


Figure C-1. Location of 2014 Residential Soil Decision Units Sampled for Lead and Arsenic IVBA.

Figure C-2. Location of 206 Residential Soil Decision Units Sampled for Lead and Arsenic IVBA.

References:

Integral. (2014) Upper Columbia River Final Beach Sediment Study Field Sampling and Data Summary Report. Prepared for Teck American Incorporated. December.

SRC. (2014) Quality Assurance Project Plan. Upper Columbia River Residential Soil Study. Washington State. Prepared for U.S. Environmental Protection Agency Region 10 and Environmental Response Team. Prepared by SRC, Inc. for Lockheed Martin. Scientific Engineering Response & Analytical Services Program. August.

TAI. (2016) Final 2016 Residential Soil Study, Quality Assurance Project Plan Addendum No. 1 to the 2014 Residential Soil Study Quality Assurance Project Plan. Prepared for Teck American Incorporated. July.

U.S. EPA (U.S. Environmental Protection Agency). (2017a) Approach That Will Be Used to Adjust Soil Arsenic and Lead Concentrations in Residential Soils Based on Relative Bioavailability (RBA) in the Upper Columbia River (UCR) Human Health Risk Assessment (HHRA). Memorandum to Monical Tonel (EPA Region 10), Marc Stifelman (EPA Region 10), David Charters (EPA ERT). U.S. Environmental Protection Agency. September.

U.S. EPA (U.S. Environmental Protection Agency). (2017b) Validated Test Method 1340: *In Vitro* Bioaccessibility Assay for Lead in Soil. U.S. Environmental Protection Agency. Available online at: https://www.epa.gov/sites/production/files/2017-03/documents/method_1340_update_vi_final_3-22-17.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2017c) Validation Assessment of *In Vitro* Arsenic Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soils and Soil-like Materials at Superfund Sites. U.S. Environmental Protection Agency. OLEM 9355.4-29. April 20, 2017.

U.S. EPA (U.S. Environmental Protection Agency). (2017d) Release of Standard Operating Procedure for an *In Vitro* Bioaccessibility Assay for Lead and Arsenic in Soil and Validation Assessment of the *In Vitro* Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soils and Soil-like Materials at Superfund Sites. Transmittal Memorandum from Schatzi Fitz-James to Superfund National Program Managers, Regions 1-10. May 5, 2017. U.S. Environmental Protection Agency. Available online at: http://semspub.epa.gov/src/document/HQ/196751.

ATTACHMENT D: Bioavailability Adjustment of Daily Oral Intake of Arsenic in a Baseline Human Health Risk Assessment: A Case Study

The issue of bioavailability of arsenic is especially important at mining, milling, and smelting sites. This is because the arsenic at these sites often exists, at least in part, as a poorly soluble sulfide, and may occur in particles of inert or insoluble material. These factors collectively tend to reduce the bioavailability of arsenic. The oral bioavailability of soil-bound arsenic largely depends on the rate at which it dissociates from the soil matrix in the gastrointestinal tract. Soil-bound arsenic is usually absorbed by the gastrointestinal tract to a lesser degree than when in more soluble forms. This reduced absorption results from the affinity between arsenic and the soil matrix, the low solubility of the chemical form of arsenic associated with the soil, or both. Thus, the bioavailability of arsenic from site soil is expected to be low for constituents that are tightly bound within the soil matrix and/or are in a form that is insoluble in the gastrointestinal tract under physiological conditions.

During the remedial investigation data collection, a site-specific bioavailability study was conducted to provide a better understanding of the oral bioavailability of arsenic in soil, which may have been affected by site-related releases. Soil arsenic relative bioavailability (RBA) was estimated from *in vitro* bioaccessibility (IVBA) measured using U.S. Environmental Protection Agency (U.S. EPA) Method 1340 (U.S. EPA, 2017a, 2017b).

The total arsenic concentrations in the test samples ranged from 29 to 6,899 mg/kg, spanning the range of levels typically seen during the Remedial Investigation. The bioaccessible fraction of arsenic does not appear to be concentration dependent with respect to total arsenic. The highest IVBA values were 57% and 54% at two locations where known efflorescent salts have been observed during site investigations; therefore, these values were considered outliers and were not used to estimate the sitewide RBA. A site-specific bioavailability adjustment factor was estimated using test results from 72 soil samples collected across the site from a combination of residential and non-residential areas (gulch areas, smelter area, and mine tailings). For this pooled data set, the RBA 50th, 90th, 95th, and 99th percentiles were estimated to be 14%, 21%, 22%, and 28%, respectively. To ensure that site risk was not underestimated at a residence and provide a health-protective estimate of site-specific bioavailability, 22% was selected as the site-specific oral bioavailability adjustment factor for use in this human health risk assessment (HHRA). The adjustment was as follows:

$$adjusted\ DI = DI \times RBA\ (fraction)$$

where DI is the daily oral intake of arsenic in soil (mg/kg/day).

This bioavailability adjustment factor was used to adjust the oral exposure from total arsenic measured in all soil samples. The test results indicate that the forms of arsenic in soil at the site are of relatively low bioavailability, when compared to U.S. EPA default value of 60% (U.S. EPA, 2012). It should be noted that the oral bioavailability adjustment factor derived herein is intended to be a site-specific value and is not intended for unvalidated use at other sites.

References:

U.S. EPA (U.S. Environmental Protection Agency). (2012) Compilation and Review of Data for Relative Bioavailability of Arsenic in Soil and Recommendations for Default Value for Relative Bioavailability. OSWER 9200.1-113. Washington, DC. December. Available online at: http://semspub.epa.gov/src/document/HQ/175339.

U.S. EPA (U.S. Environmental Protection Agency). (2017a) Standard Operating Procedure for an *In Vitro* Bioaccessibility Assay for Lead and Arsenic in Soil. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9200.2-164. July. Available online at: https://semspub.epa.gov/src/document/HQ/100000153.

U.S. EPA (U.S. Environmental Protection Agency). (2017b) Validation Assessment of the *In Vitro* Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soil and Soil-like Materials at Superfund Sites. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9355.4-29. April 20, 2017. Available online at: http://semspub.epa.gov/src/document/HQ/196751.

ATTACHMENT E: Retrospective RBA assessment to Support a Removal Decision: A Case Study

Site description: Arsenic-contaminated sediment from an industrial facility was dispersed into a residential neighborhood (most likely as fill). Sampling of residential yards revealed contamination that was largely restricted to a depth of <1 foot. Properties having soil arsenic levels greater than the action level (AL) of 40 mg/kg were identified for potential removal actions. Subsequent to the sampling for concentration, the decision was made to estimate arsenic relative bioavailability (RBA) in archived soil samples to determine which properties exceeded the AL after adjustment for RBA.

Soil arsenic concentrations, IVBA, and RBA at the site: Arsenic concentrations and *in vitro* bioaccessibility (IVBA) (Method 1340) were measured for 22 soils, each representing a residential property at the site (Table E-1). The mean arsenic concentration was 66 ± 54 (mean ± standard deviation [SD]) mg/kg (95% confidence limit [CL]: 42–90; range: 1–219). The mean IVBA ± SD was 26 ± 9% (range: 10–38).

Arsenic RBA was predicted from each IVBA by applying the validated regression model relating arsenic IVBA and arsenic RBA (U.S. EPA, 2017a, 2017b, 2017c). Arsenic IVBA was reported in units of percent; therefore, the conversion to RBA% is as follows (Equation E-1):

$$RBA\% = IVBA\% \times 0.79 + 3 \qquad\qquad\text{Eq. (E-1)}$$

The mean ± SD arsenic RBA for the 22 soils was 24 ± 7% (95% CL: 21–27; range: 11–33; 95th percentile [PCT95]: 32; Table E-1). Five of the soils had RBAs that were ≤15% (range: 11–15); the other 17 RBAs were all >20% (range 21–33). Four samples collected at depth had a mean RBA that was not significantly different from surface samples (27 ± 10%; range: 13–33; *t*-test p>0.05).

The subset of five surface soils that had RBAs ≤15% are statistical outliers; however, it suggests the possibility of clustering of soil arsenic RBA into a lower and higher category. Since this could be an indication of heterogeneity of RBA across the sampled locations, it would be reasonable to further explore the geographic distribution of the lower RBA soils as well as the nature of the arsenic contamination of the soils at the site. Heterogeneity of site RBAs can be observed when there are multiple sources of contamination and the arsenic from the different sources have different RBAs. An example of this would be a site in which soil is contaminated with smelter source material along with smelter stack emissions. Evidence for heterogeneity of contamination sources may support deriving more than one RBA to represent different locations within the site. No evidence could be obtained for multiple arsenic sources at this site (based on the nature of the industrial processes to which the contamination was attributed).

Any of several statistical metrics could be selected to represent RBA at the site, but in practice, the mean, the 95% upper confidence limit (95UCL), and the PCT95 are the most common metrics. The mean or 95UCL are typically used when calculating a central tendency exposure and the PCT95 may be used as a reasonable maximum exposure or where there is much uncertainty or heterogeneity in the measured IVBA or calculated RBA values (U.S. EPA, 1989, 2002, 2019). Factors to be considered in selecting which metric to use include uncertainty in the estimated mean (CI), evidence or concerns for source heterogeneity or spatial heterogeneity of RBA, and risk management objectives. The risk assessor selects a metric that is appropriate for the site. At this site, the 95UCL or PCT95 were considered as metrics to represent the site-wide RBA. This was based mainly on two considerations: (1) uncertainty about how well the IVBA data represented the site (it was not based on a statistical sample) and (2) the site RBA estimate was going to support removal decisions.

RBA-adjusted AL: The method used to adjust the AL will depend on the RBA assumptions that underlie the soil AL. If the RBA assumption embedded in the soil AL is 100%, then the following adjustment would be made (Equation E-2):

$$soil\ AL_{adjusted} = soil\ AL / (RBA\% / 100) \hspace{2cm} \text{Eq. (E-2)}$$

If the RBA assumption embedded in the soil AL is 60% (U.S. EPA, 2012b), then the following adjustment would be made (Equation E-3):

$$soil\ AL_{adjusted} = soil\ AL / (RBA\% / 60) \hspace{2cm} \text{Eq. (E-3)}$$

In either case, the 95UCL or PCT95 could be used to adjust the AL. Adjusted ALs based on the above equations are shown in in Table E-2. Adjustment of the AL for RBA decreased the number of properties that exceeded the AL from 12 of 18 to ≤2 of 18, depending on the specific RBA adjustment.

Table E-1. Soil Arsenic Concentrations and Corresponding IVBA and RBA					
Soil ID	**Soil Arsenic mg/kg**	**SD mg/kg**	**Arsenic IVBA %**	**SD mg/kg**	**Arsenic RBA %**
1	53	0	24	0	22
2	55	5	24	0	22
3	40	0	33	1	29
4	38	1	33	1	29
5	110	1	25	2	23
6	36	1	23	1	21
7	54	1	31	1	27
8	72	2	25	1	23
9	36	1	36	1	31
10	53	1	29	1	26
11	46	2	36	1	31
12	147	1	35	0	31
13	49	1	26	0	24
14	47	1	27	1	24
15	68	9	12	0	12
16	34	4	15	0	15
17	4	1	10	1	11
18	4	0	12	3	12
19[a]	127		38		33
20[a]	155		36		32
21[a]	219		36		31
22[a]	1		13		13
N	22		22		22
Mean	66		26		24
SD	54		9		7
LCL95	42		22		21
95UCL	90		30		27
PCT95	155		36		32

[a]Collected at depth.

LCL95, 95% lower confidence limit on the mean; IVBA, *in vitro* bioaccessibility; N, number of estimates; PCT95, 95th percentile; RBA, relative bioavailability; SD, standard deviation; 95UCL, 95% upper confidence limit on the mean

Table E-2. Examples of Action Level Adjustments Based on Site RBA

RBA Assumption in AL	Unadjusted AL[a] (ppm)	Properties Exceeding AL	Adjusted AL Based on 95UCL RBA= 27%[b] (ppm)	Properties Exceeding AL	Adjusted AL Based on PCT95 RBA= 32%[b] (ppm)	Properties Exceeding AL
RBA = 100%	40	12 of 18	148[c]	0 of 18	125[c]	1 of 18
RBA = 60%	40	12 of 18	89[d]	2 of 18	75[d]	2 of 18

[a]Unadjusted AL is the State of Connecticut Removal Management Level.
[b]Regional risk assessor would select a metric most appropriate for the site.
[c]Calculated from Equation E-2.
[d]Calculated from Equation E-3.

AL, action level; PCT95, 95th percentile; RBA, relative bioavailability; 95UCL, 95% upper confidence limit on the mean

References:

U.S. EPA (U.S. Environmental Protection Agency). (1989) Risk Assessment Guidance for Superfund Volume 1 Human Health Evaluation Manual (Part A). U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. EPA/540/1-80/0023. December. Available online at: https://www.epa.gov/risk/risk-assessment-guidance-superfund-rags-part.

U.S. EPA (U.S. Environmental Protection Agency). (2002) Calculating Upper confidence Limit for Exposure Point Concentrations at Hazardous Waste Sites. U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. OSWER 9285.6-10. July. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100CYCE.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2017a) Validated Test Method 1340: *In Vitro* Bioaccessibility Assay for Lead in Soil. U.S. Environmental Protection Agency. Available online at: https://www.epa.gov/sites/production/files/2017-03/documents/method_1340_update_vi_final_3-22-17.pdf.

U.S. EPA (U.S. Environmental Protection Agency). (2017b) Validation Assessment of *In Vitro* Arsenic Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soils and Soil-like Materials at Superfund Sites. U.S. Environmental Protection Agency. OLEM 9355.4-29 April. Available online at: http://semspub.epa.gov/src/document/HQ/196751.

U.S. EPA (U.S. Environmental Protection Agency). (2017c) Release of Standard Operating Procedure for an *In Vitro* Bioaccessibility Assay for Lead and Arsenic in Soil and Validation Assessment of the *In Vitro* Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soils and Soil-like Materials at Superfund Sites. Transmittal Memorandum from Schatzi Fitz-James to Superfund National Program Managers, Regions 1-10. May 5, 2017. U.S. Environmental Protection Agency. Available online at: https://semspub.epa.gov/src/document/HQ/100000153.

U.S. EPA (U.S. Environmental Protection Agency). (2019) Guidelines for Human Exposure Assessment. U.S. Environmental Protection Agency, Risk Assessment Forum: Washington, DC. EPA/100/B-19/001 October. Available online at: https://www.epa.gov/sites/production/files/2020-01/documents/guidelines_for_human_exposure_assessment_final2019.pdf.

ATTACHMENT F: Relative Bioavailability Adjustment of a Risk-Based Concentration for Lead: A Case Study – Adjusting RBA in the IEUBK Model and ALM

Once site-specific relative bioavailability (RBA) has been determined, adjustments can be applied to the Integrated Exposure Uptake Biokinetic Model for Lead in Children (IEUBK model) absorption fraction percent of soil lead parameter (AFP_{soil}, Figure F-1). This adjustment is as follows (Equation F-1):

$$\text{adjusted } AFP_{soil} = RBA \text{ fraction} \times 50 \qquad \text{Eq. (F-1)}$$

where the value 50 is the IEUBK model default value for the absorption fraction percent of lead in drinking water (AFP_{water}).

Site-specific adjustment of the absorption fraction percent parameters in the IEUBK model should be applied only to the corresponding medium tested for RBA (e.g., soil). Once adjustments have been applied to the AFP_{soil} parameter, the model will predict a site-specific risk-based soil lead concentration that reflects the site-specific RBA of soil lead. Concentrations of lead found throughout the site can then be compared to the adjusted risk-based concentration for decision-making purposes.

Note that different sources (i.e., smelting, foundries) may result in the need for source-specific, risk-based concentrations at one site. For example, if the source of lead contamination on one part of the site is from smelting processes and the other is from lead shot, the soil RBA (and AFP_{soil}) may vary with location. A conceptual site model is needed prior to sampling and testing for RBA to ensure accurate representation of RBA and AFP_{soil} at the site.

An average AFP_{soil} throughout the site or range-specific value can be used in the IEUBK model. Region 4 recommends using an average AFP_{soil} if the source of contamination at the site is consistent.

Example of risk-based concentration adjustment: A Region 4 site in Chattanooga, Tennessee, hereafter referred to as "the Site" applied site-specific bioavailability to adjust the risk-based concentration used for decision-making purposes. Thirty-three surface soil samples were sent to the laboratory for IVBA measurement using Method 1340 (U.S. EPA, 2017a). Samples ranged in lead concentrations from 130 to 2000 mg/kg. RBA was predicted from IVBA (U.S. EPA, 2017b). The AFP_{soil} for each soil sample was calculated using Equation F-1. The mean of AFP_{site} of all samples analyzed, 36%, was selected to represent the Site because the contamination was from one main source, which was spent foundry sands (see Table F-1). After an appropriate blood lead level had been selected (8 μg/dL), the average site-specific AFP_{soil} was used in the IEUBK model to derive an RBA-adjusted risk-based concentration (see Figure F-2). Updated parameters were also applied to the IEUBK model, resulting in a final risk-based concentration of 361 mg/kg. The concentration of 361 mg/kg then became the site-specific clean-up goal.

Total Lead (mg/kg)	IVBA Lead (mg/kg)	IVBA Fraction[a]	RBA[b]	AFP$_{soil}$
290	335	1.16	99%	49%
330	234	0.71	59%	30%
360	355	0.99	84%	42%
360	279	0.78	65%	33%
390	269	0.69	58%	29%
400	319	0.80	67%	34%
430	400	0.93	79%	39%
490	519	1.06	90%	45%
500	472	0.94	80%	40%
590	469	0.79	67%	33%
630	476	0.76	64%	32%
670	736	1.10	94%	47%
700	790	1.13	96%	48%
700	593	0.85	72%	36%
710	550	0.77	65%	33%
730	638	0.87	74%	37%
740	589	0.80	67%	34%
890	660	0.74	62%	31%
920	723	0.79	66%	33%
970	785	0.81	68%	34%
1200	992	0.83	70%	35%
1200	836	0.70	58%	29%
1200	880	0.73	62%	31%
1200	906	0.76	63%	32%
1700	1290	0.76	64%	32%
2000	1880	0.94	80%	40%
Mean		0.85	71%	36%

Table F-1. Thirty-three Soil Samples Analyzed by Method 1340 and Their Corresponding AFP$_{soil}$

[a]Calculated as IVBA fraction = IVBA lead/total lead.
[b]RBA calculated as RBA percent = $100 \times (0.878 \times$ IVBA fraction $-0.028)$.

AFP$_{soil}$, is the IEUBK model parameter absorption fraction percent for soil; IEUBK, Integrated Exposure Uptake Biokinetic Model for Lead in Children; IVBA, *in vitro* bioaccessibility; RBA, relative bioavailability

Figure F-1. Default Parameters in the IEUBK Model; Adjustments Specific to Media Tested for Bioavailability.

Figure F-2. Site-specific AFP$_{soil}$ Adjustment of Soil and Dust.

References:

U.S. EPA (U.S. Environmental Protection Agency). (2017a) Standard Operating Procedure for an *In Vitro* Bioaccessibility Assay for Lead and Arsenic in Soil. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9200.2-164. July. Available online at: https://semspub.epa.gov/src/document/HQ/100000153.

U.S. EPA (U.S. Environmental Protection Agency). (2017b) Validation Assessment of the *In Vitro* Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soil and Soil-like Materials at Superfund Sites. U.S. Environmental Protection Agency, Office of Superfund Remediation and Technology Innovation: Washington, DC. OLEM 9355.4-29. April 20, 2017. Available online at: http://semspub.epa.gov/src/document/HQ/196751.

ATTACHMENT G: Relative Bioavailability Adjustment of Absorption Fraction Parameters in the Integrated Exposure Biokinetic Model for Lead in Children and Adult Lead Methodology: Cherokee County Railroad Site Case Study

Site description: As part of the human health risk assessment (HHRA), soils were sampled at 34 locations along a historic rail line (U.S. EPA, 2014). Contamination of the rail lines occurred predominantly from use of chat from surrounding mine waste piles as ballast in the railbeds. Various sources of chat may have been used at different times in the construction of the railbeds.

Data Quality Objective (DQO): One of several objectives of the soil sampling study was to collect data on lead *in vitro* bioaccessibility (IVBA) that would provide a basis for adjusting the absorption fraction percent for soil lead (AFP_{soil}) in the U.S. Environmental Protection Agency (U.S. EPA) Integrated Exposure Uptake Biokinetic Model for Lead in Children (IEUBK model) (U.S. EPA, 1994) and absorption fraction for soil and dust (AF_{S+D}) parameter in the U.S. EPA Adult Lead Model (ALM) (U.S. EPA, 2003) for RBA at the site. The IEUBK model was used to assess risks to children exposed to rail-line soils during recreational visits to the area. The ALM was used to assess risk to workers and adolescent and adult recreational visitors.

Sampling approach: IVBA testing (U.S. EPA Method 1340, U.S. EPA, 2017) was conducted on 43 soil samples collected from the rail lines in 2013 and 2014. The samples included 31 surface soil samples (0–6 inches) and 12 subsurface samples (6–48 inches).

RBA Predicted from IVBA and Adjustments of Absorption Fraction Parameters:

IVBA was converted to RBA as follows:

$$RBA\ percent = (IVBA\ fraction \times 0.878 - 0.028) \times 100$$

where RBA is expressed as a percent and IVBA is expressed as a fraction.

The IEUBK model AFP_{soil} parameter was calculated as follows:

$$AFP_{soil} = (RBA\ percent\ /\ 100) \times 50$$

where the value 50 is the IEUBK model default value for the absorption fraction percent of lead in drinking water (AFP_{water}).

The ALM AF_{S+D} parameter was calculated as follows:

$$AF_{S+D} = (RBA\ percent\ /\ 100) \times 0.20$$

where the value 0.20 is the ALM default value for the absorption fraction for lead in water.

Results from 2013 and 2014 sampling: Table G-1 presents the lead IVBA, RBA predicted from IVBA, and AFP_{soil} for each sample. IVBA in surface soils ranged from 23% to 96%, corresponding to an RBA range of 18–82%. For locations identified as high-frequency use areas, IVBA in surface soils ranged from 23% to 86%, corresponding to an RBA range of 18–73%. For locations identified as low frequency use areas, IVBA values in surface soils ranged from 39% to 96%, corresponding to an RBA range of 32–82%. Although it is known that the ballast used in the railroad beds was originally composed of chat from surrounding mine waste piles, it is unknown whether the same lead-contaminated material

was used in constructing all railbeds. Based on uncertainty regarding the source materials, and high variability in RBA (18–82%), separate RBA, AFP_{soil}, and AF_{S+D} values were estimated based on exposure areas as follows:

IEUBK Model Adjustments to AFP_{soil}

Exposure Point	Population	Soil	Average IVBA (Fraction)	Estimated RBA	Adjusted AFP_{soil}
High-frequency use	Child recreational visitor	Surface soil	0.535	44%	22%
Low-frequency use			0.721	61%	30%

ALM Adjustments to AF_{S+D}

Exposure Point	Population	Soil	Average IVBA (fraction)	Estimated RBA	Adjusted AF_{S+D}
High-frequency use	Adolescent/adult recreational visitor	Surface soil	0.535	44%	9%
Low-frequency use			0.721	61%	12%
Site	Future worker	Surface + subsurface soil	0.608	51%	10%

Table G-1. *In vitro* Bioaccessibility and Estimated Relative Bioavailability of Lead in Rail Line Soil Samples Collected in 2013 and 2014

Sample Year	Location	Exposure Area	Depth (inch)	Total Lead (mg/kg)	IVBA (fraction)	RBA[a]	AFP_{soil}[b]
2013	CCR-SS-25B	HFR	0–6	1860	0.564	47%	23%
	CCR-SS-11A	LFR	0–6	2330	0.700	59%	29%
	CCR-SS-12B	LFR	0–6	1690	0.551	46%	23%
	CCR-SS-1A	LFR	0–6	1640	0.639	53%	27%
	CCR-SS-26A	LFR	0–6	3240	0.643	54%	27%
	CCR-SS-13A	HFR	6–12	1990	0.460	38%	19%
	CCR-SS-24B	HFR	6–12	1860	0.450	37%	18%
	CCR-SS-28A	LFR	6–12	1800	0.483	40%	20%
	CCR-SS-33A	LFR	6–12	2280	0.521	43%	21%
	CCR-SS-6A	LFR	6–12	964	0.752	63%	32%
	CCR-SS-27B	LFR	12–18	2070	0.549	45%	23%
	CCR-SS-31B	LFR	12–18	1970	0.470	38%	19%
	CCR-SS-13E	HFR	18–24	518	0.263	20%	10%
	CCR-SS-26B	LFR	18–24	1680	0.498	41%	20%
	CCR-SS-29B	LFR	18–24	1150	0.516	43%	21%
	CCR-SS-32A	LFR	18–24	2690	0.663	55%	28%
	CCR-SS-1C	LFR	24–30	637	0.764	64%	32%
2014	17A	HFR	0–6	856	0.518	43%	21%
	17B	HFR	0–6	1025	0.768	65%	32%
	17C	HFR	0–6	1833	0.863	73%	36%
	13-Baxter Springs A	HFR	0–6	2631	0.559	46%	23%
	13-Baxter Springs B	HFR	0–6	2552	0.695	58%	29%
	13-Baxter Springs C	HFR	0–6	2187	0.604	50%	25%

Table G-1. *In vitro* Bioaccessibility and Estimated Relative Bioavailability of Lead in Rail Line Soil Samples Collected in 2013 and 2014

Sample Year	Location	Exposure Area	Depth (inch)	Total Lead (mg/kg)	IVBA (fraction)	RBA[a]	AFP$_{soil}$[b]
	25A	HFR	0–6	1028	0.597	50%	25%
	25B	HFR	0–6	1035	0.407	33%	16%
	24A	HFR	0–6	1280	0.397	32%	16%
	24B	HFR	0–6	1994	0.486	40%	20%
	15A	HFR	0–6	184	0.233	18%	9%
	15B	HFR	0–6	372	0.267	21%	10%
	14A	HFR	0–6	246	0.537	44%	22%
	32A	LFR	0–6	1553	0.690	58%	29%
	32B	LFR	0–6	1876	0.913	77%	39%
	32C	LFR	0–6	1917	0.745	63%	31%
	8C	LFR	0–6	844	0.921	78%	39%
	8B	LFR	0–6	917	0.961	82%	41%
	8A	LFR	0–6	788	0.944	80%	40%
	1A	LFR	0–6	1256	0.729	61%	31%
	1B	LFR	0–6	841	0.609	51%	25%
	1C	LFR	0–6	707	0.588	49%	24%
	26A	LFR	0–6	1515	0.759	64%	32%
	26B	LFR	0–6	1460	0.814	69%	34%
	13-Lawton A	LFR	0–6	223	0.391	32%	16%
	13-Lawton B	LFR	0–6	167	0.665	56%	28%

[a]RBA = (IVBA × 0.878-0.028) × 100.
[b]Absorption fraction percent for soil for use in IEUBK model, AFP = RBA × 0.50.

AFP$_{soil}$, is the IEUBK model parameter absorption fraction percent for soil; HFR, high-frequency recreational use area; IEUBK, Integrated Exposure Uptake Biokinetic Model for Lead in Children; IVBA, *in vitro* bioaccessibility; LFR, low-frequency recreational use area; RBA, relative bioavailability

Surface Only (0–6")	Average Lead (mg/kg)	Average IVBA (fraction)	Average RBA	Average AFP$_{soil}$
High-Frequency Use	1363	0.535	44%	22%
Low-Frequency Use	1351	0.721	61%	30%
Site	1356	0.637	53%	27%

Across All Depths	Average Lead (mg/kg)	Average IVBA (fraction)	Average RBA	Average AFP$_{soil}$
High-Frequency Use	1379	0.510	42%	21%
Low-Frequency Use	1469	0.672	56%	28%
Site	1434	0.608	51%	25%

References:

U.S. EPA (U.S. Environmental Protection Agency). (1994) Technical Support Document for the Integrated Exposure Uptake Biokinetic Model for Lead in Children (v0.99d). U.S. Environmental Protection Agency, Office of Emergency and Remedial Response: Washington, DC. EPA 9285.7-22. December. Available online at: https://www.epa.gov/superfund/lead-superfund-sites-software-and-users-manuals.

U.S. EPA (U.S. Environmental Protection Agency). (2003) Recommendations of the Technical Review Workgroup for Lead for an Approach to Assessing Risks Associated with Adult Exposures to Lead in Soil. U.S. Environmental Protection Agency: Washington, DC. EPA-540-R-03-001, OSWER Directive #9385.7-54. December. Available online at: https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100A16H.txt.

U.S. EPA (U.S. Environmental Protection Agency). (2014) Baseline Human Health Risk Assessment for the Cherokee County Railroad Site Operable Unit 8 – Located in Cherokee County, Kansas. Final Draft. May 14, 2015.

U.S. EPA (U.S. Environmental Protection Agency). (2017) Release of Standard Operating Procedure for an *In Vitro* Bioaccessibility Assay for Lead and Arsenic in Soil and Validation Assessment of the *In Vitro* Bioaccessibility Assay for Predicting Relative Bioavailability of Arsenic in Soils and Soil-like Materials at Superfund Sites. Transmittal Memorandum from Schatzi Fitz-James to Superfund National Program Managers, Regions 1-10. May 5, 2017. U.S. Environmental Protection Agency. Available online at: https://semspub.epa.gov/src/document/HQ/100000153.

ATTACHMENT H: Relative Bioavailability Adjustment of Soil Lead Exposure Point Concentrations for a Time-Weighted Exposure to Soil

This example illustrates an approach to adjusting time-weighted average (TWA) soil lead exposure point concentrations (EPCs) for relative bioavailability (RBA) for use in the Integrated Exposure Uptake Biokinetic Model for Lead in Children (IEUBK model). Time weighting can be useful for assessing lead risks in exposure scenarios in which the child receptor spends time at two different locations having different soil concentrations and RBA. The calculations shown below are based on recommendations of the Technical Review Workgroup (TRW), *Assessing Intermittent or Variable Exposures and Lead Sites* (U.S. EPA, 2003) as amended by more recent recommendations of the TRW made in several site consultations. These recommendations are extended in the example calculations that follow, by incorporating RBA into the calculation of the TWA soil concentration.

Exposure scenario: Assumptions for the scenario that are pertinent to calculating the TWA soil lead concentration and RBA-adjusted TWA concentration are as follows (Table H-1):

1. Children spend 2 out of every 7 days at a camp and 5 out of 7 days at home, 3 months of each year.

2. The fraction of waking hours spent outdoors are the same at camp and at home.

3. The M_{SD} (fraction of door dust contributed by soil) is 0.7 at both locations (IEUBK model default value).

4. The air lead concentration is 0.1 mg/m^3 at both location (IEUBK model default value).

5. The soil/dust ingestion rate is the same at home and at camp (IEUBK model default values).

6. The mean soil lead concentration at the home is 100 ppm and the concentration at the camp is 700 ppm.

7. The RBA of soil at home is 0.6 (60%) and the RBA of soil at the camp is 0.8 (80%).

8. All other exposures are assumed to be the same at home and camp (IEUBK model default values).

Calculation of RBA-adjusted TWA soil and dust lead concentration: The TWA exposure is calculated by weighting the soil lead concentrations at the two locations by a weighting factor, *F*, representing the fraction of exposure that occurs at the two locations. For this scenario, *F* is calculated as follows:

$$F_{camp} = \frac{2}{7} = 0.286 \qquad\qquad\qquad \text{Eq. (H-1)}$$

$$F_{home} = 1 - F_{camp} = 0.714 \text{ Eq} \qquad\qquad\qquad \text{Eq. (H-2)}$$

Note that F_{camp} is calculated based on the exposure frequency that represents the smallest repeated exposure averaging time, in this case, 2 days per 7 days, rather than the frequency for the larger averaging time (3 months per 12 months). This approach will tend to overestimate the 12-month average lead daily intake (DI) and corresponding average blood lead, but it will not underestimate the average DI and blood

lead for the 3-month seasonal period of exposure (Lorenzana et al., 2005). Therefore, this is the more health-protective approach to time averaging the exposures.

The TWA soil exposure concentration (ppm) is calculated by apportioning the soil lead concentration according to F_{camp} and F_{home}, as follows:

$$Soil_{TWA} = 0.286 \times 700 + 0.714 \times 100 = 271 \qquad \text{Eq. (H-3)}$$

The corresponding TWA indoor dust lead concentration (ppm) is calculated as the product of the $Soil_{TWA}$ and M_{SD}, plus the contribution from air lead, as follows:

$$Dust_{TWA} = Soil_{TWA} \times 0.7 + 100 \times 0.1 = 200 \qquad \text{Eq. (H-4)}$$

The analogous calculation for the RBA-adjusted $Soil_{TWA}$ adjusts the location-specific soil concentrations by the corresponding RBAs relative to the default RBA in the IEUBK model (e.g., camp RBA/0.6). The adjustment is as follows:

$$RBA\ adjusted\ Soil_{TWA} = 0.286 \times 700 \times \frac{0.8}{0.6} + 0.714 \times 100 \times \frac{0.6}{0.6} = 338 \qquad \text{Eq. (H-5)}$$

The corresponding TWA indoor dust lead concentration is as calculated as the product of the RBA-adjusted $Soil_{TWA}$, M_{SD}, and air lead concentration, as follows:

$$RBA\ adjusted\ Dust_{TWA} = RBA\ adjusted\ Soil_{TWA} \times 0.7 + 100 \times 0.1 = 247 \qquad \text{Eq. (H-6)}$$

In this scenario, the higher RBA at camp (0.8) relative to the IEUBK model default RBA (0.6) contributes to a higher TWA soil concentration after adjustment for RBA at home and camp (338 ppm compared to 271 ppm).

Application of RBA-adjusted TWA soil lead concentrations in the IEUBK model: To predict the probability of exceeding a given blood lead concentration decision point (e.g., 5 µg/dL), the RBA-adjusted TWA soil lead concentration would be used as input to the IEUBK model. The default bioavailability parameters in the IEUBK model (AFP_{soil}, AFP_{dust}) should not be adjusted when RBA-adjusted soil concentrations are inputs to the model.

References

Lorenzana, R.M., Troast, R., Klotzbach, J.M., Follansbee, M.H., Diamond, G.L. (2005) Issues related to time averaging in modeling risks associated with intermittent exposures to lead. Risk Anal. 25(1):169–178.

U.S. EPA (U.S. Environmental Protection Agency). (2003) Assessing Intermittent or Variable Exposures and Lead Site. U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response: Washington, DC. OSWER 9285.7-76. EPA-540-R-03-008. Available online at: http://semspub.epa.gov/src/document/HQ/176288.

Table H-1. RBA-adjusted TWA Soil and Dust Lead Concentrations for Camp Scenario			
Parameter	**Unit**	**Value**	**Equation**
Days at camp	day/week	2	
Days in exposure interval	day/week	7	
Soil lead at camp	ppm	700	
Soil lead at home	ppm	100	
RBA at camp		0.80	
RBA at home		0.60	
IEUBK model default M_{SD}		0.7	
IEUBK model default air lead	$\mu g/m^3$	0.1	
IEUBK model default RBA		0.60	
Fraction of time at camp		0.286	Eq. H-1
Fraction of time at home		0.714	Eq. H-2
Soil lead TWA	ppm	271	Eq. H-3
Dust lead TWA	ppm	200	Eq. H-4
RBA-adjusted soil lead TWA	ppm	338	Eq. H-5
RBA-adjusted dust lead TWA	ppm	247	Eq. H-6

M_{SD}, soil-dust mass transfer coefficient; RBA, relative bioavailability; TWA, time-weighted average